1
|
Lockwood P, Burton C, Woznitza N, Shaw T. Assessing the barriers and enablers to the implementation of the diagnostic radiographer musculoskeletal X-ray reporting service within the NHS in England: a systematic literature review. BMC Health Serv Res 2023; 23:1270. [PMID: 37974199 PMCID: PMC10655396 DOI: 10.1186/s12913-023-10161-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2023] [Accepted: 10/16/2023] [Indexed: 11/19/2023] Open
Abstract
INTRODUCTION The United Kingdom (UK) government's healthcare policy in the early 1990s paved the way adoption of the skills mix development and implementation of diagnostic radiographers' X-ray reporting service. Current clinical practice within the public UK healthcare system reflects the same pressures of increased demand in patient imaging and limited capacity of the reporting workforce (radiographers and radiologists) as in the 1990s. This study aimed to identify, define and assess the longitudinal macro, meso, and micro barriers and enablers to the implementation of the diagnostic radiographer musculoskeletal X-ray reporting service in the National Healthcare System (NHS) in England. METHODS Multiple independent databases were searched, including PubMed, Ovid MEDLINE; Embase; CINAHL, and Google Scholar, as well as journal databases (Scopus, Wiley), healthcare databases (NHS Evidence Database; Cochrane Library) and grey literature databases (OpenGrey, GreyNet International, and the British Library EthOS depository) and recorded in a PRISMA flow chart. A combination of keywords, Boolean logic, truncation, parentheses and wildcards with inclusion/exclusion criteria and a time frame of 1995-2022 was applied. The literature was assessed against Joanna Briggs Institute's critical appraisal checklists. With meta-aggregation to synthesize each paper, and coded using NVivo, with context grouped into macro, meso, and micro-level sources and categorised into subgroups of enablers and barriers. RESULTS The wide and diverse range of data (n = 241 papers) identified barriers and enablers of implementation, which were categorised into measures of macro, meso, and micro levels, and thematic categories of context, culture, environment, and leadership. CONCLUSION The literature since 1995 has reframed the debates on implementation of the radiographer reporting role and has been instrumental in shaping clinical practice. There has been clear influence upon both meso (professional body) and macro-level (governmental/health service) policies and guidance, that have shaped change at micro-level NHS Trust organisations. There is evidence of a shift in culturally intrenched legacy perspectives within and between different meso-level professional bodies around skills mix acceptance and role boundaries. This has helped shape capacity building of the reporting workforce. All of which have contributed to conceptual understandings of the skills mix workforce within modern radiology services.
Collapse
Affiliation(s)
- P Lockwood
- Present address: School of Allied Health Professions, Faculty of Medicine, Health and Social Care, Canterbury Christ Church University, North Holmes Road, Canterbury, Kent, UK.
| | - C Burton
- Present address: School of Allied Health Professions, Faculty of Medicine, Health and Social Care, Canterbury Christ Church University, North Holmes Road, Canterbury, Kent, UK
| | - N Woznitza
- Present address: School of Allied Health Professions, Faculty of Medicine, Health and Social Care, Canterbury Christ Church University, North Holmes Road, Canterbury, Kent, UK
- Radiology Department, University College London Hospitals NHS Foundation Trust, 235 Euston Road, London, UK
| | - T Shaw
- Present address: School of Allied Health Professions, Faculty of Medicine, Health and Social Care, Canterbury Christ Church University, North Holmes Road, Canterbury, Kent, UK
| |
Collapse
|
2
|
Sigler A, Wu J, Pfaff A, Adetunji O, Nam P, James D, Burton C, Shi H. Repeated Low-Level Blast Exposure Alters Urinary and Serum Metabolites. Metabolites 2023; 13:metabo13050638. [PMID: 37233679 DOI: 10.3390/metabo13050638] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2023] [Revised: 04/28/2023] [Accepted: 05/06/2023] [Indexed: 05/27/2023] Open
Abstract
Repeated exposure to low-level blast overpressures can produce biological changes and clinical sequelae that resemble mild traumatic brain injury (TBI). While recent efforts have revealed several protein biomarkers for axonal injury during repetitive blast exposure, this study aims to explore potential small molecule biomarkers of brain injury during repeated blast exposure. This study evaluated a panel of ten small molecule metabolites involved in neurotransmission, oxidative stress, and energy metabolism in the urine and serum of military personnel (n = 27) conducting breacher training with repeated exposure to low-level blasts. The metabolites were analyzed using HPLC-tandem mass spectrometry, and the Wilcoxon signed-rank test was used for statistical analysis to compare the levels of pre-blast and post-blast exposures. Urinary levels of homovanillic acid (p < 0.0001), linoleic acid (p = 0.0030), glutamate (p = 0.0027), and serum N-acetylaspartic acid (p = 0.0006) were found to be significantly altered following repeated blast exposure. Homovanillic acid concentration decreased continuously with subsequent repeat exposure. These results suggest that repeated low-level blast exposures can produce measurable changes in urine and serum metabolites that may aid in identifying individuals at increased risk of sustaining a TBI. Larger clinical studies are needed to extend the generalizability of these findings.
Collapse
Affiliation(s)
- Austin Sigler
- Department of Chemistry, Missouri University of Science and Technology, Rolla, MO 65409, USA
| | - Jiandong Wu
- Department of Chemistry, Missouri University of Science and Technology, Rolla, MO 65409, USA
| | - Annalise Pfaff
- Department of Chemistry, Missouri University of Science and Technology, Rolla, MO 65409, USA
| | - Olajide Adetunji
- Department of Chemistry, Missouri University of Science and Technology, Rolla, MO 65409, USA
| | - Paul Nam
- Department of Chemistry, Missouri University of Science and Technology, Rolla, MO 65409, USA
| | | | - Casey Burton
- Department of Chemistry, Missouri University of Science and Technology, Rolla, MO 65409, USA
- Phelps Health, Rolla, MO 65401, USA
| | - Honglan Shi
- Department of Chemistry, Missouri University of Science and Technology, Rolla, MO 65409, USA
| |
Collapse
|
3
|
Greenlee JL, Stelter CR, Hickey E, Burton C, Carlson M, Winter MA. Using the Three-Minute Speech Sample to Examine the Parent-Adolescent Relationship in Autistic Youth: A Qualitative Analysis. J Autism Dev Disord 2023:10.1007/s10803-023-05942-7. [PMID: 37022577 DOI: 10.1007/s10803-023-05942-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/18/2023] [Indexed: 04/07/2023]
Abstract
PURPOSE This qualitative study examines autistic adolescents' perception of the quality of their relationship with their parent using the Three Minute Speech Sample. METHODS Twenty autistic youth (13-17 years; 83% male) spoke, uninterrupted, for three minutes about their thoughts and feelings regarding their mothers. Audio-recorded speech samples were transcribed and coded for emergent themes. RESULTS Adolescents highlighted emotional support and acceptance in the context of their relationship, support mothers provide for mental health, love and caring, efforts to build the relationship through shared activities, and areas of adolescent-parent conflict. CONCLUSION The TMSS is a low cost, low burden method by which autistic adolescents can comfortably and effectively self-report the quality of their relationship with their parent/caregiver.
Collapse
Affiliation(s)
| | | | - Emily Hickey
- Waisman Center, University of Wisconsin-Madison, Madison, USA
| | - Casey Burton
- Department of Psychology, Virginia Commonwealth University, Richmond, USA
| | - Megan Carlson
- Developmental and Behavioral Sciences, Children's Mercy Kansas City, 730 High St, Easton, PA, 18042, USA
| | - Marcia A Winter
- Department of Psychology, Virginia Commonwealth University, Richmond, USA
| |
Collapse
|
4
|
Saunders B, Burton C, van der Windt DA, Myers H, Chester R, Pincus T, Wynne-Jones G. Patients' and clinicians' perspectives towards primary care consultations for shoulder pain: qualitative findings from the Prognostic and Diagnostic Assessment of the Shoulder (PANDA-S) programme. BMC Musculoskelet Disord 2023; 24:1. [PMID: 36588148 PMCID: PMC9805906 DOI: 10.1186/s12891-022-06059-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/13/2022] [Accepted: 12/06/2022] [Indexed: 01/03/2023] Open
Abstract
BACKGROUND Clinical management of musculoskeletal shoulder pain can be challenging due to diagnostic uncertainty, variable prognosis and limited evidence for long-term treatment benefits. The UK-based PANDA-S programme (Prognostic And Diagnostic Assessment of the Shoulder) is investigating short and long-term shoulder pain outcomes. This paper reports linked qualitative research exploring patients' and clinicians' views towards primary care consultations for shoulder pain. METHODS Semi-structured interviews were conducted with 24 patients and 15 primary care clinicians. Twenty-two interviews (11 patients, 11 clinicians) were conducted as matched patient-clinician 'dyads'. Data were analysed thematically. RESULTS Clinicians reported attempts to involve patients in management decisions; however, there was variation in whether patients preferred treatment choice, or for decisions to be clinician-led. Some patients felt uncertain about the decisions made, due to a lack of discussion about available management options. Many General Practitioners expressed a lack of confidence in diagnosing the underlying cause of shoulder pain. Patients reported either not being given a diagnosis, or receiving different diagnoses from different professionals, resulting in confusion. Whilst clinicians reported routinely discussing prognosis of shoulder pain, patients reported that prognosis was not raised. Patients also expressed concern that their shoulder pain could be caused by serious pathology; however, clinicians felt that this was not a common concern for patients. CONCLUSIONS Findings showed disparities between patients' and clinicians' views towards shoulder pain consultations, indicating a need for improved patient-clinician communication. Findings will inform the design of an intervention to support treatment and referral decisions for shoulder pain that will be tested in a randomised controlled trial.
Collapse
Affiliation(s)
- B. Saunders
- grid.9757.c0000 0004 0415 6205Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Keele, Staffordshire ST5 5BG UK
| | - C. Burton
- grid.9757.c0000 0004 0415 6205Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Keele, Staffordshire ST5 5BG UK
| | - D. A. van der Windt
- grid.9757.c0000 0004 0415 6205Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Keele, Staffordshire ST5 5BG UK
| | - H. Myers
- grid.9757.c0000 0004 0415 6205Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Keele, Staffordshire ST5 5BG UK ,grid.9757.c0000 0004 0415 6205Clinical Trials Unit, Keele University, Keele, UK
| | - R. Chester
- grid.8273.e0000 0001 1092 7967School of Health Sciences, Faculty of Medicine and Health, University of East Anglia, Norwich Research Park, Norwich, UK
| | - T. Pincus
- grid.5491.90000 0004 1936 9297Faculty of Environmental and Life Sciences (FELS), University of Southampton, Southampton, UK
| | - G. Wynne-Jones
- grid.9757.c0000 0004 0415 6205Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Keele, Staffordshire ST5 5BG UK
| |
Collapse
|
5
|
Rasmussen L, Foulks Z, Wu J, Burton C, Shi H. Establishing pteridine metabolism in a progressive isogenic breast cancer cell model - part II. Metabolomics 2022; 18:27. [PMID: 35482254 PMCID: PMC10030290 DOI: 10.1007/s11306-022-01885-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/22/2022] [Accepted: 04/01/2022] [Indexed: 11/26/2022]
Abstract
INTRODUCTION Determining the biological significance of pteridines in cancer development and progression remains an important step in understanding the altered levels of urinary pteridines seen in certain cancers. Our companion study revealed that several folate-derived pteridines and lumazines correlated with tumorigenicity in an isogenic, progressive breast cancer cell model, providing direct evidence for the tumorigenic origin of pteridines. OBJECTIVES This study sought to elucidate the pteridine biosynthetic pathway in a progressive breast cancer model via direct pteridine dosing to determine how pteridine metabolism changes with tumorigenicity. METHODS First, MCF10AT breast cancer cells were dosed individually with 15 pteridines to determine which pteridines were being metabolized and what metabolic products were being produced. Second, pteridines that were significantly metabolized were dosed individually across the progressive breast cancer cell model (MCF10A, MCF10AT, and MCF10ACA1a) to determine the relationship between each metabolic reaction and breast cancer tumorigenicity. RESULTS Several pteridines were found to have altered metabolism in breast cancer cell lines, including pterin, isoxanthopterin, xanthopterin, sepiapterin, 6-biopterin, lumazine, and 7-hydroxylumazine (p < 0.05). In particular, isoxanthopterin and 6-biopterin concentrations were differentially expressed (p < 0.05) with respect to tumorigenicity following dosing with pterin and sepiapterin, respectively. Finally, the pteridine biosynthetic pathway in breast cancer cells was proposed based on these findings. CONCLUSIONS This study, along with its companion study, demonstrates that pteridine metabolism becomes disrupted in breast cancer tumor cells. This work highlights several key metabolic reactions within the pteridine biosynthetic pathway that may be targeted for further investigation and clinical applications.
Collapse
Affiliation(s)
- Lindsey Rasmussen
- Department of Chemistry, Missouri University of Science and Technology, 400 W 11th Street, 65409, Rolla, MO, USA
| | - Zachary Foulks
- Department of Chemistry, Missouri University of Science and Technology, 400 W 11th Street, 65409, Rolla, MO, USA
| | - Jiandong Wu
- Department of Chemical and Biochemical Engineering, Missouri University of Science and Technology, 65409, Rolla, MO, USA
| | - Casey Burton
- Department of Chemistry, Missouri University of Science and Technology, 400 W 11th Street, 65409, Rolla, MO, USA.
- Center for Biomedical Research, Missouri University of Science and Technology, 65409, Rolla, MO, USA.
- Phelps Health, 65401, Rolla, MO, USA.
| | - Honglan Shi
- Department of Chemistry, Missouri University of Science and Technology, 400 W 11th Street, 65409, Rolla, MO, USA.
- Center for Biomedical Research, Missouri University of Science and Technology, 65409, Rolla, MO, USA.
| |
Collapse
|
6
|
Babatunde OO, Bucknall M, Burton C, Forsyth JJ, Corp N, Gwilym S, Paskins Z, van der Windt DA. Long-term clinical and socio-economic outcomes following wrist fracture: a systematic review and meta-analysis. Osteoporos Int 2022; 33:753-782. [PMID: 34766193 DOI: 10.1007/s00198-021-06214-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/27/2021] [Accepted: 10/18/2021] [Indexed: 12/11/2022]
Abstract
UNLABELLED A comprehensive review of studies shows that patients with wrist fracture, aged over 50 years, experience pain and functional limitation long after fracture. This is associated with increased healthcare costs, and reduced quality of life. Understanding factors that predict poor outcomes is important for future healthcare policy and planning. PURPOSE To summarise and appraise evidence on the prognosis and long-term clinical and socio-economic outcomes following wrist fracture among adults aged 50 years and over. METHODS Five databases (MEDLINE, EMBASE, AMED, CINAHL-P and PsycINFO) were comprehensively searched (supplemented by a grey-literature search) from inception till June 2021 for prospective/retrospective cohort studies of patients (≥ 50 years) with a history of wrist fracture and reporting long-term (≥ 6 months) outcomes. Peer study selection, data extraction and risk of bias assessment were conducted. A random effects meta-analysis was used to summarise estimates of pain and function outcomes. RESULTS 78 studies (n = 688,041 patients) were included. Patients report persistent moderate to severe pain (range: 7.5%-62%) and functional limitations (range: 5.5-78%) up to 12-months or later after wrist fracture. Mean Patient-Rated Wrist Evaluation (PRWE) score for pain and function (9 studies, n = 1759 patients) was 15.23 (95%CI 12.77, 17.69) at 6-months to 13-years follow-up. Mean disabilities of the arm, shoulder and hand (DASH) score (9 studies, n = 1346 patients) was 13.82 (95%CI 12.71, 14.93)( at 6- to 17-months follow-up. A 10-20% increase in healthcare encounters in the first 12-months after fracture was observed. Twelve prognostic factors were associated with poor long-term outcomes. CONCLUSION Evidence shows that a high proportion of people aged over 50 years with wrist fracture experience pain and functional limitation > 6 months after fracture. This is associated with increased healthcare costs, and reduced quality of life. Exploratory evidence was found for several candidate prognostic factors. Their predictive performance needs to be investigated further. PROSPERO CRD42018116478.
Collapse
Affiliation(s)
- O O Babatunde
- Keele University School of Medicine Staffordshire, Keele, ST5 5BG, UK.
| | - M Bucknall
- Keele University School of Medicine Staffordshire, Keele, ST5 5BG, UK
| | - C Burton
- Keele University School of Medicine Staffordshire, Keele, ST5 5BG, UK
| | - J J Forsyth
- Centre for Health and Development, Staffordshire University, Stoke-on-Trent, ST4 2DF, UK
| | - N Corp
- Keele University School of Medicine Staffordshire, Keele, ST5 5BG, UK
| | - S Gwilym
- Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford University, Oxford, UK
| | - Z Paskins
- Keele University School of Medicine Staffordshire, Keele, ST5 5BG, UK
- Haywood Academic Rheumatology Centre, Midlands Partnership NHS Foundation Trust, Stoke on Trent, ST6 7AG, UK
| | - D A van der Windt
- Keele University School of Medicine Staffordshire, Keele, ST5 5BG, UK
| |
Collapse
|
7
|
Garcia-Pertierra S, Das S, Burton C, Barnes D, Murgia D, Anderson D, Kulendra N, Harris K, Forster K. Surgical management of intrathoracic wooden skewers migrating from the stomach and duodenum in dogs: 11 cases (2014-2020). J Small Anim Pract 2022; 63:403-411. [PMID: 35083753 PMCID: PMC9303292 DOI: 10.1111/jsap.13474] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2021] [Revised: 10/08/2021] [Accepted: 10/31/2021] [Indexed: 11/30/2022]
Abstract
Objectives To describe the clinical presentation, management and outcome of cases presenting with intrathoracic wooden skewers originating from the abdominal gastrointestinal tract. Materials and Methods Clinical records of dogs presented and treated for an intrathoracic wooden skewer were reviewed from June to August 2020. Data included signalment, clinical presentation, duration of clinical signs, haematological and biochemical abnormalities, diagnostic imaging findings, surgical procedure, postoperative complications and outcome. Results Eleven dogs were included in the study. In all cases, the foreign body was identified as a wooden skewer. The most common clinical signs were anorexia/hyporexia (n=7), vomiting/regurgitation (n=7), lethargy (n=6), pyrexia (n=4) and gait abnormalities/lameness (n=3). CT correctly identified a wooden skewer in all cases when performed (n=7). A coeliotomy combined with transdiaphragmatic thoracotomy was performed in six of 11 cases (55%), a coeliotomy combined with median sternotomy in four of 11 cases (36%) and a median sternotomy alone was performed in one case. Foreign bodies penetrated from the stomach (n=10) or the duodenum (n=1). Intrathoracic trauma was most commonly identified to the lungs (n=3) and pericardium (n=3). Complications occurred in three of 11 cases (27%), two minor and one resulting in death. Ten of the 11 cases (91%) survived to discharge. Long‐term outcome was available for seven of 11 cases (66%), all of them excellent. Clinical Significance Despite the challenges of managing wooden skewers penetrating the thoracic cavity from the abdominal gastrointestinal tract, the majority of the patients are stable to undergo diagnostic procedures, surgical exploration and management with low morbidity and excellent short‐ and long‐term prognosis.
Collapse
Affiliation(s)
- S Garcia-Pertierra
- Hospital for Small Animals, Royal (Dick) School of Veterinary Studies and Roslin Institute, Midlothian, EH25 9RG, UK
| | - S Das
- Davies Veterinary Specialists, Hertfordshire, SG5 3HR, UK
| | - C Burton
- Davies Veterinary Specialists, Hertfordshire, SG5 3HR, UK
| | - D Barnes
- Dick White Referrals, Cambridge, CB8 0UH, UK
| | - D Murgia
- Dick White Referrals, Cambridge, CB8 0UH, UK
| | - D Anderson
- Anderson Moores Veterinary Specialists, Hampshire, SO21 2LL, UK
| | - N Kulendra
- North Downs Specialist Referrals, Bletchingley, RH1 4QP, UK
| | - K Harris
- Southern Counties Veterinary Specialists, Hampshire, BH24 3JW, UK
| | - K Forster
- North Downs Specialist Referrals, Bletchingley, RH1 4QP, UK
| |
Collapse
|
8
|
Yang Q, Lin TS, Burton C, Park S, Ma Y. Corrigendum to: Physicochemical insights of irradiation-enhanced hydroxyl radical generation from ZnO nanoparticles. Toxicol Res (Camb) 2021; 10:1228. [PMID: 34950448 DOI: 10.1093/toxres/tfab099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2015] [Revised: 02/12/2020] [Accepted: 10/21/2015] [Indexed: 11/14/2022] Open
Abstract
[This corrects the article DOI: 10.1039/c5tx00384a.].
Collapse
Affiliation(s)
- Qingbo Yang
- Department of Chemistry and Center for Single Nanoparticle, Single Cell, and Single Molecule Monitoring, Missouri University of Science and Technology, Rolla, MO 65409, USA
| | - Tien-Sung Lin
- Department of Chemistry, Washington University in St. Louis, St. Louis, MO 63130, USA
| | - Casey Burton
- Department of Chemistry and Center for Single Nanoparticle, Single Cell, and Single Molecule Monitoring, Missouri University of Science and Technology, Rolla, MO 65409, USA
| | - Sungho Park
- Department of Chemistry, Washington University in St. Louis, St. Louis, MO 63130, USA
| | - Yinfa Ma
- Department of Chemistry and Center for Single Nanoparticle, Single Cell, and Single Molecule Monitoring, Missouri University of Science and Technology, Rolla, MO 65409, USA
| |
Collapse
|
9
|
Forster K, Cutando LS, Ladlow J, Anderson D, Burton C, Das S, Gibson S, Kulendra N, Emmerson T, Baines S, Rutherford L, Paulino RD, Fontanini R, Compagnone K, De La Puerta B. Outcome of caudal superficial epigastric axial pattern flaps in dogs and cats: 70 cases (2007-2020). J Small Anim Pract 2021; 63:128-135. [PMID: 34937131 DOI: 10.1111/jsap.13467] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2021] [Revised: 11/25/2021] [Accepted: 12/02/2021] [Indexed: 11/29/2022]
Abstract
OBJECTIVES To describe the outcome and complications associated with the use of caudal superficial epigastric axial pattern flaps in dogs and cats. MATERIAL AND METHODS Multicentre retrospective review and descriptive study of clinical records of dogs and cats having undergone caudal superficial epigastric axial pattern flaps between 2007 and 2020. Data retrieved included signalment, aetiology of surgical defect, tumour type, presence/absence of clean surgical margins, presence/absence of post-operative wound infection, use of peri- and post-operative antibiotics, duration of anaesthesia, duration of surgery, presence and duration of hypothermia, presence and duration of hypotension, presence/absence of post-operative surgical drain and length of caudal superficial epigastric axial pattern flap. The incidence of complications and outcomes were documented. RESULTS Seventy cases met the inclusion criteria; 51 dogs and 19 cats. In dogs, 67% of cases developed complications (59% minor, 8% major) and 33% had uneventful wound healing. In cats, 53% of cases developed complications, (47% minor, 5% major) and 47% had uneventful wound healing. In dogs, the percentage of cases experiencing dehiscence, necrosis, seroma, oedema and post-operative infection was 31%, 29%, 26%, 26% and 16% respectively. In cats, this was 26%, 16%, 11%, 0% and 5% respectively. A good overall outcome was seen in 77% of dogs and 79% of cats. A poor overall outcome was seen in 4% of dogs and 0% of cats. CLINICAL SIGNIFICANCE Caudal superficial epigastric axial pattern flaps are traditionally thought more robust than other flaps, yet complication rates remain high, despite a high overall success rate.
Collapse
Affiliation(s)
- K Forster
- North Downs Specialist Referrals, The Friesian Buildings 3 and 4, Bletchingley RH1 4QP, UK
| | - L S Cutando
- The Ralph Veterinary Referral Centre, Fourth Avenue Globe Business Park, Marlow SL7 1 YG, UK
| | - J Ladlow
- Hamilton Specialist Referrals, Cressex Business Park, High Wycombe HP12 3SD, UK
| | - D Anderson
- Anderson Moores, The Granary, Bunstead Barns, Poles Lane, Hursley, Winchester, Hampshire, SO21 2LL, UK
| | - C Burton
- Davies Veterinary Specialists, Manor Farm Business Park, Higham Gobion, Hertfordshire, SG5 3HR, UK
| | - S Das
- Davies Veterinary Specialists, Manor Farm Business Park, Higham Gobion, Hertfordshire, SG5 3HR, UK
| | - S Gibson
- Davies Veterinary Specialists, Manor Farm Business Park, Higham Gobion, Hertfordshire, SG5 3HR, UK
| | - N Kulendra
- North Downs Specialist Referrals, The Friesian Buildings 3 and 4, Bletchingley RH1 4QP, UK
| | - T Emmerson
- North Downs Specialist Referrals, The Friesian Buildings 3 and 4, Bletchingley RH1 4QP, UK
| | - S Baines
- Willows Veterinary Centre and Referral Service, Shirley, Solihull, West Midlands B90 4NH, UK
| | - L Rutherford
- The Royal Veterinary College, Hertfordshire, AL9 7TA, UK
| | - R D Paulino
- Dick White Referrals, Station Farm, Six Mile Bottom, Cambridge, CB8 0UH, UK
| | - R Fontanini
- Hospital for Small Animals, Royal (Dick) School of Veterinary Studies and Roslin Institute, Easter Bush Campus, Midlothian, EH25 9RG, UK
| | - K Compagnone
- Northwest Veterinary Specialists, Delamere House, Ashville Point, Beechwood, Sutton Weaver, Runcorn WA7 3FW, UK
| | - B De La Puerta
- North Downs Specialist Referrals, The Friesian Buildings 3 and 4, Bletchingley RH1 4QP, UK
| |
Collapse
|
10
|
Abstract
INTRODUCTION Pteridines include folate-derived metabolites that have been putatively associated with certain cancers in clinical studies. However, their biological significance in cancer metabolism and role in cancer development and progression remains poorly understood. OBJECTIVES The purpose of this study was to examine the effects of tumorigenicity on pteridine metabolism by studying a panel of 15 pteridine derivatives using a progressive breast cancer cell line model with and without folic acid dosing. METHODS The MCF10A progressive breast cancer model, including sequentially derived MCF10A (benign), MCF10AT (premalignant), and MCF10CA1a (malignant) cell lines were dosed with 0, 100, and 250 mg/L folic acid. Pteridines were analyzed in both intracellular and extracellular contexts using an improved high-performance liquid chromatography-tandem mass spectrometry method. RESULTS Pteridines were located predominately in the extracellular media. Folic acid dosing increased extracellular levels of pterin, 6-hydroxylumazine, xanthopterin, 6-hydroxymethylpterin, and 6-carboxypterin in a dose-dependent manner. In particular, pterin and 6-hydroxylumazine levels were positively correlated with tumorigenicity upon folate dosing. CONCLUSIONS Folic acid is a primary driver for pteridine metabolism in human breast cell. Higher folate levels contribute to increased formation and excretion of pteridine derivatives to the extracellular media. In breast cancer, this metabolic pathway becomes dysregulated, resulting in the excretion of certain pteridine derivatives and providing in vitro evidence for the observation of elevated pteridines in the urine of breast cancer patients. Finally, this study reports a novel use of the MCF10A progressive breast cancer model for metabolomics applications that may readily be applied to other metabolites of interest.
Collapse
Affiliation(s)
- Lindsey Rasmussen
- Department of Chemistry, Missouri University of Science and Technology, 400 W 11th Street, Rolla, MO, 65409, USA
| | - Zachary Foulks
- Department of Chemistry, Missouri University of Science and Technology, 400 W 11th Street, Rolla, MO, 65409, USA
| | - Casey Burton
- Department of Chemistry, Missouri University of Science and Technology, 400 W 11th Street, Rolla, MO, 65409, USA.
- Phelps Health, Rolla, MO, 65401, USA.
| | - Honglan Shi
- Department of Chemistry, Missouri University of Science and Technology, 400 W 11th Street, Rolla, MO, 65409, USA.
| |
Collapse
|
11
|
Housten AJ, Okere UC, Colditz GA, Ma C, Liu J, Harriss C, Lin NU, Rooney M, Dill J, Popalzai M, Badiu J, Huang K, Burton C, Peterson L. Developing an Academic and Community Practice Collaborative Care Model for Metastatic Breast Cancer Care: A Protocol using the Dynamic Adaptation Process (Preprint). JMIR Res Protoc 2021; 11:e35736. [PMID: 35475732 PMCID: PMC9361152 DOI: 10.2196/35736] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2021] [Revised: 03/22/2022] [Accepted: 04/22/2022] [Indexed: 11/21/2022] Open
Abstract
Background Metastatic breast cancer (MBC) remains incurable despite significant treatment advances. Coordinating care for patients with MBC can be challenging given the various treatment options, available clinical trials, and frequent need for ancillary services. To optimize MBC care, we designed a project for adapting and developing an academic and community practice collaborative care model for MBC care (Project ADAPT), based on the Ending Metastatic Breast Cancer for Everyone (EMBRACE) program developed at Dana Farber Cancer Institute. Objective We aim to describe the implementation science–based study design and innovative components of Project ADAPT. Methods Project ADAPT uses the Dynamic Adaptation Process informed by the Exploration, Preparation, Implementation, Sustainment framework. Washington University School of Medicine (WUSM) partnered with 3 community hospitals in the St. Louis region covering rural and urban settings. The exploration and preparation phases provide patient and provider feedback on current referral practices to finalize the approach for the implementation phase. At the implementation phase, we will enroll patients with MBC at these 3 community sites to evaluate potential collaborative care at WUSM and assess the impact of this collaborative care model on referral satisfaction and acceptability for patients with MBC and their providers. Patients may then return to their community site for care or continue to receive part of their care at WUSM. We are incorporating virtual and digital health strategies to improve MBC care coordination in order to minimize patient burden. Results The exploration phase is ongoing. As of August 2021, we have recruited 21 patient and provider participants to complete surveys of the current collaborative care process at WUSM. Using a 2-tailed paired t test, 44 patients (including 10 patients from the exploration phase) and 32 oncologists are required to detect an effect size of 0.5 with 80% power at a level of significance of .05. Throughout this phase and in preparation for the implementation phase, we have iteratively updated and refined our surveys for the implementation phase based on testing of our data collection instruments. Our partner sites are in various stages of the single institutional review board (IRB) approval process. We have ongoing engagement with all partner sites, which has helped solidify our participant recruitment strategies and design patient-friendly recruitment materials. In addition, we have included a patient advocate on the research team. Members of the research team have launched a single IRB Support Network at WUSM to create a repository of the single IRB procedures in order to streamline the partner site onboarding process and facilitate enhanced collaboration across institutions. Conclusions With this robust model, we expect that patients with MBC will receive optimal care regardless of geographical location and the model will improve patient and provider experiences when navigating the health system. International Registered Report Identifier (IRRID) DERR1-10.2196/35736
Collapse
Affiliation(s)
- Ashley J Housten
- Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO, United States
| | - Uzoma Charles Okere
- Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO, United States
| | - Graham A Colditz
- Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO, United States
| | - Cynthia Ma
- Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States
| | - Jingxia Liu
- Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO, United States
| | - Courtney Harriss
- Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO, United States
| | - Nancy U Lin
- Department of Medicine, Harvard Medical School, Boston, MA, United States
| | - Melissa Rooney
- Missouri Baptist Medical Center, St. Louis, MO, United States
| | - Jennifer Dill
- Missouri Baptist Medical Center, St. Louis, MO, United States
| | - Muhammad Popalzai
- SIH Cancer Institute, Southern Illinois Healthcare, Carterville, IL, United States
| | - Jennifer Badiu
- SIH Cancer Institute, Southern Illinois Healthcare, Carterville, IL, United States
| | - Kan Huang
- Phelps Health Delbert Day Cancer Institute, Rolla, MO, United States
| | - Casey Burton
- Phelps Health Delbert Day Cancer Institute, Rolla, MO, United States
| | - Lindsay Peterson
- Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States
| |
Collapse
|
12
|
Raikwar SP, Thangavel R, Ahmed ME, Selvakumar GP, Kempuraj D, Wu K, Khan O, Bazley K, Bussinger B, Kukulka K, Zaheer S, Iyer SS, Govindarajan R, Burton C, James D, Zaheer A. Real-Time Noninvasive Bioluminescence, Ultrasound and Photoacoustic Imaging in NFκB-RE-Luc Transgenic Mice Reveal Glia Maturation Factor-Mediated Immediate and Sustained Spatio-Temporal Activation of NFκB Signaling Post-Traumatic Brain Injury in a Gender-Specific Manner. Cell Mol Neurobiol 2021; 41:1687-1706. [PMID: 32785863 PMCID: PMC8188847 DOI: 10.1007/s10571-020-00937-9] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2020] [Accepted: 08/05/2020] [Indexed: 12/15/2022]
Abstract
Neurotrauma especially traumatic brain injury (TBI) is the leading cause of death and disability worldwide. To improve upon the early diagnosis and develop precision-targeted therapies for TBI, it is critical to understand the underlying molecular mechanisms and signaling pathways. The transcription factor, nuclear factor kappa B (NFκB), which is ubiquitously expressed, plays a crucial role in the normal cell survival, proliferation, differentiation, function, as well as in disease states like neuroinflammation and neurodegeneration. Here, we hypothesized that real-time noninvasive bioluminescence molecular imaging allows rapid and precise monitoring of TBI-induced immediate and rapid spatio-temporal activation of NFκB signaling pathway in response to Glia maturation factor (GMF) upregulation which in turn leads to neuroinflammation and neurodegeneration post-TBI. To test and validate our hypothesis and to gain novel mechanistic insights, we subjected NFκB-RE-Luc transgenic male and female mice to TBI and performed real-time noninvasive bioluminescence imaging (BLI) as well as photoacoustic and ultrasound imaging (PAI). Our BLI data revealed that TBI leads to an immediate and sustained activation of NFκB signaling. Further, our BLI data suggest that especially in male NFκB-RE-Luc transgenic mice subjected to TBI, in addition to brain, there is widespread activation of NFκB signaling in multiple organs. However, in the case of the female NFκB-RE-Luc transgenic mice, TBI induces a very specific and localized activation of NFκB signaling in the brain. Further, our microRNA data suggest that TBI induces significant upregulation of mir-9-5p, mir-21a-5p, mir-34a-5p, mir-16-3p, as well as mir-155-5p within 24 h and these microRNAs can be successfully used as TBI-specific biomarkers. To the best of our knowledge, this is one of the first and unique study of its kind to report immediate and sustained activation of NFκB signaling post-TBI in a gender-specific manner by utilizing real-time non-invasive BLI and PAI in NFκB-RE-Luc transgenic mice. Our study will prove immensely beneficial to gain novel mechanistic insights underlying TBI, unravel novel therapeutic targets, as well as enable us to monitor in real-time the response to innovative TBI-specific precision-targeted gene and stem cell-based precision medicine.
Collapse
Affiliation(s)
- Sudhanshu P Raikwar
- Department of Neurology, School of Medicine, University of Missouri, Columbia, MO, USA.
- Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, MO, USA.
- Harry S. Truman Memorial Veterans' Hospital, Columbia, MO, USA.
| | - Ramasamy Thangavel
- Department of Neurology, School of Medicine, University of Missouri, Columbia, MO, USA
- Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, MO, USA
- Harry S. Truman Memorial Veterans' Hospital, Columbia, MO, USA
| | - Mohammad Ejaz Ahmed
- Department of Neurology, School of Medicine, University of Missouri, Columbia, MO, USA
- Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, MO, USA
- Harry S. Truman Memorial Veterans' Hospital, Columbia, MO, USA
| | - Govindhasamy Pushpavathi Selvakumar
- Department of Neurology, School of Medicine, University of Missouri, Columbia, MO, USA
- Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, MO, USA
- Harry S. Truman Memorial Veterans' Hospital, Columbia, MO, USA
| | - Duraisamy Kempuraj
- Department of Neurology, School of Medicine, University of Missouri, Columbia, MO, USA
- Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, MO, USA
- Harry S. Truman Memorial Veterans' Hospital, Columbia, MO, USA
| | - Kristopher Wu
- Department of Neurology, School of Medicine, University of Missouri, Columbia, MO, USA
- Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, MO, USA
| | - Osaid Khan
- Department of Neurology, School of Medicine, University of Missouri, Columbia, MO, USA
- Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, MO, USA
| | - Kieran Bazley
- Department of Neurology, School of Medicine, University of Missouri, Columbia, MO, USA
- Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, MO, USA
| | - Bret Bussinger
- Department of Neurology, School of Medicine, University of Missouri, Columbia, MO, USA
- Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, MO, USA
| | - Klaudia Kukulka
- Department of Neurology, School of Medicine, University of Missouri, Columbia, MO, USA
- Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, MO, USA
| | - Smita Zaheer
- Department of Neurology, School of Medicine, University of Missouri, Columbia, MO, USA
- Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, MO, USA
| | - Shankar S Iyer
- Department of Neurology, School of Medicine, University of Missouri, Columbia, MO, USA
- Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, MO, USA
- Harry S. Truman Memorial Veterans' Hospital, Columbia, MO, USA
| | - Raghav Govindarajan
- Department of Neurology, School of Medicine, University of Missouri, Columbia, MO, USA
| | | | | | - Asgar Zaheer
- Department of Neurology, School of Medicine, University of Missouri, Columbia, MO, USA.
- Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, MO, USA.
- Harry S. Truman Memorial Veterans' Hospital, Columbia, MO, USA.
| |
Collapse
|
13
|
Northend M, Wilson W, Osborne W, Fox CP, Davies AJ, El‐Sharkawi D, Phillips EH, Sim HW, Sadullah S, Shah N, Peng YY, Qureshi I, Addada J, Mora RF, Phillips N, Kuhnl A, Davies E, Wrench D, McKay P, Karpha I, Cowley A, Karim R, Challenor S, Singh V, Burton C, Auer R, Williams C, Broom A, Roddie C, Townsend W. POLATUZUMAB VEDOTIN WITH BENDAMUSTINE AND RITUXIMAB FOR RELAPSED/REFRACTORY HIGH‐GRADE B‐CELL LYMPHOMA: THE UK EXPERIENCE. Hematol Oncol 2021. [DOI: 10.1002/hon.86_2880] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- M. Northend
- University College London Hospitals NHS Foundation Trust Department of Haematology London UK
| | - W. Wilson
- Cancer Research UK & UCL Cancer Trials Centre Haematology Trials Team London UK
| | - W. Osborne
- The Newcastle‐upon‐Tyne Hospitals NHS Foundation Trust Department of Haematology Newcastle‐upon‐Tyne UK
| | - C. P. Fox
- Nottingham University Hospitals NHS Trust Department of Haematology Nottingham UK
| | - A. J Davies
- University of Southampton Southampton Cancer Research UK/NIHR Experimental Cancer Medicines Centre Southampton UK
| | - D. El‐Sharkawi
- The Royal Marsden NHS Foundation Trust Department of Haematology London UK
| | - E. H. Phillips
- University of Manchester The Christie NHS Foundation Trust Manchester UK
| | - H. W. Sim
- London North West University Healthcare NHS Trust Department of Haematology London UK
| | - S. Sadullah
- James Paget University Hospitals NHS Foundation Trust Department of Haematology Great Yarmouth UK
| | - N. Shah
- Norfolk & Norwich University Hospitals NHS Foundation Trust Department of Haematology Norwich UK
| | - Y. Y. Peng
- St George's University Hospital NHS Foundation Trust Department of Haematology London UK
| | - I. Qureshi
- University Hospitals Birmingham NHS Foundation Trust Department of Haematology Birmingham UK
| | - J. Addada
- University Hospitals of Derby & Burton NHS Foundation Trust Department of Haematology Derby UK
| | - R. F. Mora
- Nottingham University Hospitals NHS Trust Department of Haematology Nottingham UK
| | - N. Phillips
- University Hospital of North Midlands NHS Trust Department of Haematology Stoke‐on‐Trent UK
| | - A. Kuhnl
- King's College Hospital NHS Foundation Trust Department of Haematology London UK
| | - E. Davies
- Manchester University NHS Foundation Trust Department of Haematology London UK
| | - D. Wrench
- Guy's & St Thomas' Hospitals NHS Foundation Trust Department of Haematology London UK
| | - P. McKay
- Beatson West of Scotland Cancer Centre Department of Haematology Glasgow UK
| | - I. Karpha
- The Clatterbridge Cancer Centre NHS Foundation Trust Department of Haematology Liverpool UK
| | - A. Cowley
- East Sussex Healthcare NHS Trust Department of Haematology East Sussex UK
| | - R. Karim
- Dorset Healthcare University NHS Foundation Trust Department of Haematology Dorchester UK
| | - S. Challenor
- Royal Cornwall NHS Trust Department of Haematology Truro UK
| | - V. Singh
- Aintree University Hospital Department of Haematology Liverpool UK
| | - C. Burton
- Leeds Teaching Hospitals NHS Trust Department of Haematology Leeds UK
| | - R. Auer
- Bart's Health NHS Trust Department of Haemato‐Oncology London UK
| | - C. Williams
- Northumbria Healthcare NHS Foundation Trust Department of Haematology Hexham UK
| | - A. Broom
- Western General Hospital Department of Haematology Edinburgh UK
| | - C. Roddie
- University College London Hospitals NHS Foundation Trust Department of Haematology London UK
| | - W. Townsend
- University College London Hospitals NHS Foundation Trust Department of Haematology London UK
| |
Collapse
|
14
|
Booth S, Kirkwood A, Johnson P, Barrington S, Gallop‐Evans E, Peggs K, Warbey V, Burton C, Ardavan A, Phillips B, Lawrie E, Pike L, Northend M, Clifton‐Hadley L, Jenner R, Collins GP. ANIMATE: A PHASE II STUDY OF NIVOLUMAB IN TRANSPLANT ELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY CLASSIC HODGKIN LYMPHOMA. Hematol Oncol 2021. [DOI: 10.1002/hon.159_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- S. Booth
- Oxford University Hospitals Department of Haematology Oxford UK
| | - A. Kirkwood
- UCL Cancer Institute CR UK and UCL Cancer Trials Centre London UK
| | - P. Johnson
- University of Southampton Department of Medicine London UK
| | - S. Barrington
- King’s College London King’s College London and Guys’ & St Thomas PET Imaging Centre London UK
| | - E. Gallop‐Evans
- Velindre University NHS Trust Department of Oncology Cardiff UK
| | - K. Peggs
- University College London Hospitals Haematology London UK
| | - V. Warbey
- King’s College London King’s College London and Guys’ & St Thomas PET Imaging Centre London UK
| | - C. Burton
- Leeds Cancer Centre Haematology Leeds UK
| | - A. Ardavan
- University of Oxford Department of Physics Oxford UK
| | - B. Phillips
- University of Manchester and Manchester Academic Health Science Centre Division of Cancer Science Manchester UK
| | - E. Lawrie
- UCL Cancer Institute CR UK and UCL Cancer Trials Centre London UK
| | - L. Pike
- King’s College London King’s College London and Guys’ & St Thomas PET Imaging Centre London UK
| | - M. Northend
- UCL Cancer Institute CR UK and UCL Cancer Trials Centre London UK
| | | | - R. Jenner
- UCL Cancer Institute CR UK and UCL Cancer Trials Centre London UK
| | - G. P. Collins
- Oxford University Hospitals Department of Haematology Oxford UK
| |
Collapse
|
15
|
Barrans SL, Cucco F, Davies J, van Hoppe M, Mell T, Mercer K, Stanton L, Caddy J, Tooze R, Burton C, Westhead D, Du M, Davies A, Johnson P. MOLECULAR HIGH GRADE (MHG) GENE EXPRESSION PROFILE IN DLBCL IS ENRICHED AMONG PATIENTS WITH EARLY TREATMENT FAILURE. Hematol Oncol 2021. [DOI: 10.1002/hon.12_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- S. L Barrans
- Leeds Teaching Hospitals HMDS Institute of Oncology Leeds UK
| | - F Cucco
- University of Cambridge Department of Pathology Cambridge UK
| | - J Davies
- University of Leeds Bioinformatics Group Faculty of Biological sciences Leeds UK
| | - M van Hoppe
- Leeds Teaching Hospitals HMDS Institute of Oncology Leeds UK
| | - T Mell
- Leeds Teaching Hospitals HMDS Institute of Oncology Leeds UK
| | - K Mercer
- University of Southampton SCTU Southampton UK
| | - l Stanton
- University of Southampton SCTU Southampton UK
| | - J Caddy
- University of Southampton SCTU Southampton UK
| | - R Tooze
- University or Leeds School of medicine Leeds UK
| | - C Burton
- Leeds Teaching Hospitals HMDS Institute of Oncology Leeds UK
| | - D Westhead
- University of Leeds Bioinformatics Group Faculty of Biological sciences Leeds UK
| | - M Du
- University of Cambridge Department of Pathology Cambridge UK
| | - A Davies
- University of Southampton SCTU Southampton UK
| | - P Johnson
- University of Southampton Medicine Southampton UK
| |
Collapse
|
16
|
Crouch S, Painter D, Barrans S, Roman E, Beer P, Lacy S, Cooke S, Webster N, Glover P, Hoppe S, Campbell PJ, Hodson DJ, Patmore R, Burton C, Smith AG, Tooze R. MOLECULAR SUBCLUSTERS OF FOLLICULAR LYMPHOMA: A REPORT FROM THE UK'S HAEMATOLOGICAL MALIGNANCY RESEARCH NETWORK. Hematol Oncol 2021. [DOI: 10.1002/hon.40_2879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- S. Crouch
- University of York Epidemiology and Cancer Statistics Group Department of Health Sciences York UK
| | - D. Painter
- University of York Epidemiology and Cancer Statistics Group Department of Health Sciences York UK
| | - S. Barrans
- Leeds Teaching Hospitals NHS Trust Haematological Malignancy Diagnostic Service Leeds UK
| | - E. Roman
- University of York Epidemiology and Cancer Statistics Group Department of Health Sciences York UK
| | - P. Beer
- University of Glasgow Glasgow Precision Oncology Laboratory Glasgow UK
| | - S. Lacy
- University of York Epidemiology and Cancer Statistics Group Department of Health Sciences York UK
| | - S. Cooke
- University of Glasgow Glasgow Precision Oncology Laboratory Glasgow UK
| | - N. Webster
- Leeds Teaching Hospitals NHS Trust Haematological Malignancy Diagnostic Service Leeds UK
| | - P. Glover
- Leeds Teaching Hospitals NHS Trust Haematological Malignancy Diagnostic Service Leeds UK
| | - S. Hoppe
- Leeds Teaching Hospitals NHS Trust Haematological Malignancy Diagnostic Service Leeds UK
| | - P. J. Campbell
- Wellcome Trust Sanger Institute, Cancer Ageing and Somatic Mutation Programme Cambridge UK
| | - D. J. Hodson
- University of Cambridge Wellcome–MRC CambridgeStem Cell Institute Cambridge UK
| | - R. Patmore
- Hull University Teaching Hospitals NHS Trust Queen's Centre for Oncology and Haematology Hull UK
| | - C. Burton
- Leeds Teaching Hospitals NHS Trust Haematological Malignancy Diagnostic Service Leeds UK
| | - A. G. Smith
- University of York Epidemiology and Cancer Statistics Group Department of Health Sciences York UK
| | - R. Tooze
- Leeds Teaching Hospitals NHS Trust Haematological Malignancy Diagnostic Service Leeds UK
| |
Collapse
|
17
|
Davies A, McKay P, Osborne W, Stanton L, Tansley‐Hancock O, Lawrence M, Mercer K, Allen A, Pottinger B, Zhelyazkova A, Miall F, Rafferty J, Sale B, Cucco F, Nunn L, Coleman A, Griffiths G, Du MQ, Burton C, Barrons S, Johnson P. 9P GAIN PREDICTS OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) TREATED WITH R‐GEMOX +/‐ ATEZOLIZUMAB. ARGO: A RANDOMISED PHASE II STUDY. Hematol Oncol 2021. [DOI: 10.1002/hon.11_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- A Davies
- University of Southampton Southampton Cancer Research UK (CRUK) Centre CRUK/NIHR Experimental Cancer Medicines Centre CRUK Southampton Clinical Trials Unit Southampton UK
| | - P McKay
- Beatson West of Scotland Cancer Centre Department of Haematology Glasgow UK
| | - W Osborne
- Freeman Hospital The Newcastle upon Tyne Hospitals NHS Foundation Trust Department of Haematology Newcastle UK
| | - L Stanton
- University of Southampton Southampton Cancer Research UK (CRUK) Centre CRUK/NIHR Experimental Cancer Medicines Centre CRUK Southampton Clinical Trials Unit Southampton UK
| | - O Tansley‐Hancock
- University of Southampton Southampton Cancer Research UK (CRUK) Centre CRUK/NIHR Experimental Cancer Medicines Centre CRUK Southampton Clinical Trials Unit Southampton UK
| | - M Lawrence
- University of Southampton Southampton Cancer Research UK (CRUK) Centre CRUK/NIHR Experimental Cancer Medicines Centre CRUK Southampton Clinical Trials Unit Southampton UK
| | - K Mercer
- University of Southampton Southampton Cancer Research UK (CRUK) Centre CRUK/NIHR Experimental Cancer Medicines Centre CRUK Southampton Clinical Trials Unit Southampton UK
| | - A Allen
- University of Southampton Southampton Cancer Research UK (CRUK) Centre CRUK/NIHR Experimental Cancer Medicines Centre CRUK Southampton Clinical Trials Unit Southampton UK
| | - B Pottinger
- Royal Cornwall Hospitals NHS Trust Department of Haematology Truro UK
| | - A Zhelyazkova
- The Pennine Acute Hospitals NHS Trust Department of Haematology Manchester UK
| | - F Miall
- University Hospitals of Leicester NHS Trust Department of Haematology Leicester UK
| | - J Rafferty
- Patient Representative, c/o CRUK Southampton Clinical Trials Unit Southampton UK
| | - B Sale
- University of Southampton Southampton Cancer Research UK (CRUK) Centre CRUK/NIHR Experimental Cancer Medicines Centre CRUK Southampton Clinical Trials Unit Southampton UK
| | - F Cucco
- University of Cambridge Department of Pathology Cambridge UK
| | - L Nunn
- University of Southampton Southampton Cancer Research UK (CRUK) Centre CRUK/NIHR Experimental Cancer Medicines Centre CRUK Southampton Clinical Trials Unit Southampton UK
| | - A Coleman
- University of Southampton Southampton Cancer Research UK (CRUK) Centre CRUK/NIHR Experimental Cancer Medicines Centre CRUK Southampton Clinical Trials Unit Southampton UK
| | - G Griffiths
- University of Southampton Southampton Cancer Research UK (CRUK) Centre CRUK/NIHR Experimental Cancer Medicines Centre CRUK Southampton Clinical Trials Unit Southampton UK
| | - M. Q Du
- University of Cambridge Department of Pathology Cambridge UK
| | - C Burton
- Leeds Cancer Centre Haematological Malignancies Diagnostic Service Leeds UK
| | - S Barrons
- Leeds Cancer Centre Haematological Malignancies Diagnostic Service Leeds UK
| | - P Johnson
- University of Southampton Southampton Cancer Research UK (CRUK) Centre CRUK/NIHR Experimental Cancer Medicines Centre CRUK Southampton Clinical Trials Unit Southampton UK
| |
Collapse
|
18
|
Shotton R, Kirkwood AA, Northend M, Fathoala D, Burton K, Ferguson G, Aiken L, Shrubsole C, Henry L, Owen M, Oliver R, Martinez‐Calle N, Etherington A, Gallop‐Evans E, Burton C, Miall F, Osborne W, Dieu R, McKay P, Ardeshna K, Collins GP, Phillips E. REAL WORLD OUTCOMES AND RESPONSES TO SECOND‐LINE THERAPY IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA: A MULTICENTRE UK STUDY. Hematol Oncol 2021. [DOI: 10.1002/hon.106_2880] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- R. Shotton
- The Christie NHS Foundation Trust Medical oncology Manchester UK
| | - A. A. Kirkwood
- UCL Cancer institute University College London Cancer Research UK and UCL Cancer Trials Centre London UK
| | - M. Northend
- University College Hospital University College London Haematology Dept London UK
| | - D. Fathoala
- University College Hospital University College London Haematology Dept London UK
| | - K. Burton
- Oxford University Hospitals NHS Foundation Trust Haematology Dept Oxford UK
| | - G. Ferguson
- Beatson West of Scotland Cancer Centre Haematology Dept Glasgow UK
| | - L. Aiken
- Bart’s Health NHS Trust Haemato‐Oncology Dept London UK
| | - C. Shrubsole
- Newcastle upon Tyne Hospitals NHS Foundation Trust Haematology Dept Newcastle UK
| | - L. Henry
- University Hospitals of Leicester Haematology Dept Leicester UK
| | - M. Owen
- Leeds Cancer Centre Leeds UK
| | - R. Oliver
- University Hospitals Bristol Haematology Dept Bristol UK
| | | | | | | | | | - F. Miall
- University Hospitals of Leicester Haematology Dept Leicester UK
| | - W. Osborne
- Newcastle upon Tyne Hospitals NHS Foundation Trust Haematology Dept Newcastle UK
| | - R. Dieu
- Bart’s Health NHS Trust Haemato‐Oncology Dept London UK
| | - P. McKay
- Beatson West of Scotland Cancer Centre Haematology Dept Glasgow UK
| | - K. Ardeshna
- University College Hospital University College London Haematology Dept London UK
| | - G. P. Collins
- Oxford University Hospitals NHS Foundation Trust Haematology Dept Oxford UK
| | - E. Phillips
- The Christie NHS Foundation Trust NIHR Manchester Biomedical Research Centre and University of Manchester Manchester UK
| |
Collapse
|
19
|
Frood R, Burton C, Tsoumpas C, Frangi AF, Gleeson F, Patel C, Scarsbrook A. Baseline PET/CT imaging parameters for prediction of treatment outcome in Hodgkin and diffuse large B cell lymphoma: a systematic review. Eur J Nucl Med Mol Imaging 2021; 48:3198-3220. [PMID: 33604689 PMCID: PMC8426243 DOI: 10.1007/s00259-021-05233-2] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2020] [Accepted: 02/01/2021] [Indexed: 12/13/2022]
Abstract
Purpose To systematically review the literature evaluating clinical utility of imaging metrics derived from baseline fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) for prediction of progression-free (PFS) and overall survival (OS) in patients with classical Hodgkin lymphoma (HL) and diffuse large B cell lymphoma (DLBCL). Methods A search of MEDLINE/PubMed, Web of Science, Cochrane, Scopus and clinicaltrials.gov databases was undertaken for articles evaluating PET/CT imaging metrics as outcome predictors in HL and DLBCL. PRISMA guidelines were followed. Risk of bias was assessed using the Quality in Prognosis Studies (QUIPS) tool. Results Forty-one articles were included (31 DLBCL, 10 HL). Significant predictive ability was reported in 5/20 DLBCL studies assessing SUVmax (PFS: HR 0.13–7.35, OS: HR 0.83–11.23), 17/19 assessing metabolic tumour volume (MTV) (PFS: HR 2.09–11.20, OS: HR 2.40–10.32) and 10/13 assessing total lesion glycolysis (TLG) (PFS: HR 1.078–11.21, OS: HR 2.40–4.82). Significant predictive ability was reported in 1/4 HL studies assessing SUVmax (HR not reported), 6/8 assessing MTV (PFS: HR 1.2–10.71, OS: HR 1.00–13.20) and 2/3 assessing TLG (HR not reported). There are 7/41 studies assessing the use of radiomics (4 DLBCL, 2 HL); 5/41 studies had internal validation and 2/41 included external validation. All studies had overall moderate or high risk of bias. Conclusion Most studies are retrospective, underpowered, heterogenous in their methodology and lack external validation of described models. Further work in protocol harmonisation, automated segmentation techniques and optimum performance cut-off is required to develop robust methodologies amenable for clinical utility. Supplementary Information The online version contains supplementary material available at 10.1007/s00259-021-05233-2.
Collapse
Affiliation(s)
- R Frood
- Department of Nuclear Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, UK. .,Leeds Institute of Health Research, University of Leeds, Leeds, UK.
| | - C Burton
- Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - C Tsoumpas
- Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK
| | - A F Frangi
- Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.,Centre for Computational Imaging and Simulation Technologies in Biomedicine (CISTIB), School of Computing and School of Medicine, University of Leeds, Leeds, UK.,Medical Imaging Research Center (MIRC), University Hospital Gasthuisberg, KU Leuven, Leuven, Belgium
| | - F Gleeson
- Department of Radiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | - C Patel
- Department of Nuclear Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - A Scarsbrook
- Department of Nuclear Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, UK.,Leeds Institute of Health Research, University of Leeds, Leeds, UK
| |
Collapse
|
20
|
Moore G, Rickard H, Stevenson D, Aranega-Bou P, Pitman J, Crook A, Davies K, Spencer A, Burton C, Easterbrook L, Love HE, Summers S, Welch SR, Wand N, Thompson KA, Pottage T, Richards KS, Dunning J, Bennett A. Detection of SARS-CoV-2 within the healthcare environment: a multi-centre study conducted during the first wave of the COVID-19 outbreak in England. J Hosp Infect 2021; 108:189-196. [PMID: 33259882 PMCID: PMC7831847 DOI: 10.1016/j.jhin.2020.11.024] [Citation(s) in RCA: 76] [Impact Index Per Article: 25.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2020] [Revised: 11/25/2020] [Accepted: 11/25/2020] [Indexed: 12/14/2022]
Abstract
BACKGROUND Understanding how severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is spread within the hospital setting is essential in order to protect staff, implement effective infection control measures, and prevent nosocomial transmission. METHODS The presence of SARS-CoV-2 in the air and on environmental surfaces around hospitalized patients, with and without respiratory symptoms, was investigated. Environmental sampling was undertaken within eight hospitals in England during the first wave of the coronavirus disease 2019 outbreak. Samples were analysed using reverse transcription polymerase chain reaction (PCR) and virus isolation assays. FINDINGS SARS-CoV-2 RNA was detected on 30 (8.9%) of 336 environmental surfaces. Cycle threshold values ranged from 28.8 to 39.1, equating to 2.2 x 105 to 59 genomic copies/swab. Concomitant bacterial counts were low, suggesting that the cleaning performed by nursing and domestic staff across all eight hospitals was effective. SARS-CoV-2 RNA was detected in four of 55 air samples taken <1 m from four different patients. In all cases, the concentration of viral RNA was low and ranged from <10 to 460 genomic copies/m3 air. Infectious virus was not recovered from any of the PCR-positive samples analysed. CONCLUSIONS Effective cleaning can reduce the risk of fomite (contact) transmission, but some surface types may facilitate the survival, persistence and/or dispersal of SARS-CoV-2. The presence of low or undetectable concentrations of viral RNA in the air supports current guidance on the use of specific personal protective equipment for aerosol-generating and non-aerosol-generating procedures.
Collapse
Affiliation(s)
- G Moore
- National Infection Service, Public Health England, Porton Down, Salisbury, UK.
| | - H Rickard
- National Infection Service, Public Health England, Porton Down, Salisbury, UK
| | - D Stevenson
- National Infection Service, Public Health England, Porton Down, Salisbury, UK
| | - P Aranega-Bou
- National Infection Service, Public Health England, Porton Down, Salisbury, UK
| | - J Pitman
- National Infection Service, Public Health England, Porton Down, Salisbury, UK
| | - A Crook
- National Infection Service, Public Health England, Porton Down, Salisbury, UK
| | - K Davies
- National Infection Service, Public Health England, Porton Down, Salisbury, UK
| | - A Spencer
- National Infection Service, Public Health England, Porton Down, Salisbury, UK
| | - C Burton
- National Infection Service, Public Health England, Porton Down, Salisbury, UK
| | - L Easterbrook
- National Infection Service, Public Health England, Porton Down, Salisbury, UK
| | - H E Love
- National Infection Service, Public Health England, Porton Down, Salisbury, UK
| | - S Summers
- National Infection Service, Public Health England, Porton Down, Salisbury, UK
| | - S R Welch
- National Infection Service, Public Health England, Porton Down, Salisbury, UK
| | - N Wand
- National Infection Service, Public Health England, Porton Down, Salisbury, UK
| | - K-A Thompson
- National Infection Service, Public Health England, Porton Down, Salisbury, UK
| | - T Pottage
- National Infection Service, Public Health England, Porton Down, Salisbury, UK
| | - K S Richards
- National Infection Service, Public Health England, Porton Down, Salisbury, UK
| | - J Dunning
- Emerging Infections and Zoonoses Unit, National Infection Service, Public Health England, Colindale, London, UK; NIHR Health Protection Research Unit in Emerging Infections and Zoonoses, Liverpool, UK
| | - A Bennett
- National Infection Service, Public Health England, Porton Down, Salisbury, UK
| |
Collapse
|
21
|
Rosmalen JGM, Burton C, Carson A, Cosci F, Frostholm L, Lehnen N, Olde Hartman TC, Rask CU, Rymaszewska J, Stone J, Tak LM, Witthöft M, Löwe B. The European Training Network ETUDE (Encompassing Training in fUnctional Disorders across Europe): a new research and training program of the EURONET-SOMA network recruiting 15 early stage researchers. J Psychosom Res 2021; 141:110345. [PMID: 33385705 DOI: 10.1016/j.jpsychores.2020.110345] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/14/2020] [Accepted: 12/15/2020] [Indexed: 10/22/2022]
Affiliation(s)
- J G M Rosmalen
- University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Dimence Group, Deventer, the Netherlands.
| | - C Burton
- University of Sheffield, Sheffield, UK
| | - A Carson
- University of Edinburgh, Edinburgh, UK
| | - F Cosci
- University of Florence, Florence, Italy
| | | | - N Lehnen
- Technical University Munich, Munich, Germany
| | | | - C U Rask
- Aarhus University Hospital, Aarhus, Denmark
| | | | - J Stone
- University of Edinburgh, Edinburgh, UK
| | - L M Tak
- Dimence Group, Deventer, the Netherlands
| | - M Witthöft
- Johannes Gutenberg-University, Mainz, Germany
| | - B Löwe
- University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| |
Collapse
|
22
|
Kempuraj D, Ahmed ME, Selvakumar GP, Thangavel R, Raikwar SP, Zaheer SA, Iyer SS, Govindarajan R, Nattanmai Chandrasekaran P, Burton C, James D, Zaheer A. Acute Traumatic Brain Injury-Induced Neuroinflammatory Response and Neurovascular Disorders in the Brain. Neurotox Res 2020; 39:359-368. [PMID: 32955722 PMCID: PMC7502806 DOI: 10.1007/s12640-020-00288-9] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2020] [Revised: 09/12/2020] [Accepted: 09/14/2020] [Indexed: 02/07/2023]
Abstract
Acute traumatic brain injury (TBI) leads to neuroinflammation, neurodegeneration, cognitive decline, psychological disorders, increased blood-brain barrier (BBB) permeability, and microvascular damage in the brain. Inflammatory mediators secreted from activated glial cells, neurons, and mast cells are implicated in the pathogenesis of TBI through secondary brain damage. Abnormalities or damage to the neurovascular unit is the indication of secondary injuries in the brain after TBI. However, the precise mechanisms of molecular and ultrastructural neurovascular alterations involved in the pathogenesis of acute TBI are not yet clearly understood. Moreover, currently, there are no precision-targeted effective treatment options to prevent the sequelae of TBI. In this study, mice were subjected to closed head weight-drop-induced acute TBI and evaluated neuroinflammatory and neurovascular alterations in the brain by immunofluorescence staining or quantitation by enzyme-linked immunosorbent assay (ELISA) procedure. Mast cell stabilizer drug cromolyn was administered to inhibit the neuroinflammatory response of TBI. Results indicate decreased level of pericyte marker platelet-derived growth factor receptor-beta (PDGFR-β) and BBB-associated tight junction proteins junctional adhesion molecule-A (JAM-A) and zonula occludens-1 (ZO-1) in the brains 7 days after weight-drop-induced acute TBI as compared with the brains from sham control mice indicating acute TBI-associated BBB/tight junction protein disruption. Further, the administration of cromolyn drug significantly inhibited acute TBI-associated decrease of PDGFR-β, JAM-A, and ZO-1 in the brain. These findings suggest that acute TBI causes BBB/tight junction damage and that cromolyn administration could protect this acute TBI-induced brain damage as well as its long-time consequences.
Collapse
Affiliation(s)
- Duraisamy Kempuraj
- Department of Neurology, School of Medicine, University of Missouri, 1 Hospital Drive, Columbia, MO, USA. .,The Center for Translational Neuroscience, School of Medicine, University of Missouri, 1 Hospital Drive, Columbia, MO, USA. .,Harry S. Truman Memorial Veterans Hospital, U.S. Department of Veterans Affairs, Columbia, MO, USA.
| | - Mohammad Ejaz Ahmed
- Department of Neurology, School of Medicine, University of Missouri, 1 Hospital Drive, Columbia, MO, USA.,The Center for Translational Neuroscience, School of Medicine, University of Missouri, 1 Hospital Drive, Columbia, MO, USA.,Harry S. Truman Memorial Veterans Hospital, U.S. Department of Veterans Affairs, Columbia, MO, USA
| | - Govindhasamy Pushpavathi Selvakumar
- Department of Neurology, School of Medicine, University of Missouri, 1 Hospital Drive, Columbia, MO, USA.,The Center for Translational Neuroscience, School of Medicine, University of Missouri, 1 Hospital Drive, Columbia, MO, USA.,Harry S. Truman Memorial Veterans Hospital, U.S. Department of Veterans Affairs, Columbia, MO, USA
| | - Ramasamy Thangavel
- Department of Neurology, School of Medicine, University of Missouri, 1 Hospital Drive, Columbia, MO, USA.,The Center for Translational Neuroscience, School of Medicine, University of Missouri, 1 Hospital Drive, Columbia, MO, USA.,Harry S. Truman Memorial Veterans Hospital, U.S. Department of Veterans Affairs, Columbia, MO, USA
| | - Sudhanshu P Raikwar
- Department of Neurology, School of Medicine, University of Missouri, 1 Hospital Drive, Columbia, MO, USA.,The Center for Translational Neuroscience, School of Medicine, University of Missouri, 1 Hospital Drive, Columbia, MO, USA.,Harry S. Truman Memorial Veterans Hospital, U.S. Department of Veterans Affairs, Columbia, MO, USA
| | - Smita A Zaheer
- Department of Neurology, School of Medicine, University of Missouri, 1 Hospital Drive, Columbia, MO, USA.,The Center for Translational Neuroscience, School of Medicine, University of Missouri, 1 Hospital Drive, Columbia, MO, USA
| | - Shankar S Iyer
- Department of Neurology, School of Medicine, University of Missouri, 1 Hospital Drive, Columbia, MO, USA.,The Center for Translational Neuroscience, School of Medicine, University of Missouri, 1 Hospital Drive, Columbia, MO, USA.,Harry S. Truman Memorial Veterans Hospital, U.S. Department of Veterans Affairs, Columbia, MO, USA
| | - Raghav Govindarajan
- Department of Neurology, School of Medicine, University of Missouri, 1 Hospital Drive, Columbia, MO, USA
| | | | | | | | - Asgar Zaheer
- Department of Neurology, School of Medicine, University of Missouri, 1 Hospital Drive, Columbia, MO, USA. .,The Center for Translational Neuroscience, School of Medicine, University of Missouri, 1 Hospital Drive, Columbia, MO, USA. .,Harry S. Truman Memorial Veterans Hospital, U.S. Department of Veterans Affairs, Columbia, MO, USA.
| |
Collapse
|
23
|
Sigler A, He X, Bose M, Cristea A, Liu W, Nam PKS, James D, Burton C, Shi H. Simultaneous Determination of Eight Urinary Metabolites by HPLC-MS/MS for Noninvasive Assessment of Traumatic Brain Injury. J Am Soc Mass Spectrom 2020; 31:1910-1917. [PMID: 32700913 DOI: 10.1021/jasms.0c00181] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
Traumatic brain injury (TBI) is a serious public health concern for which sensitive and objective diagnostic methods remain lacking. While advances in neuroimaging have improved diagnostic capabilities, the complementary use of molecular biomarkers can provide clinicians with additional insight into the nature and severity of TBI. In this study, a panel of eight metabolites involved in distinct pathophysiological processes related to concussion was quantified using high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). Specifically, the newly developed method can simultaneously determine urinary concentrations of glutamic acid, homovanillic acid, 5-hydroxyindoleacetic acid, methionine sulfoxide, lactic acid, pyruvic acid, N-acetylaspartic acid, and F2α-isoprostane without intensive sample preparation or preconcentration. The method was systematically validated to assess sensitivity (method detection limits: 1-20 μg/L), accuracy (81-124% spike recoveries in urine), and reproducibility (relative standard deviation: 4-12%). The method was ultimately applied to a small cohort of urine specimens obtained from healthy college student volunteers. The method presented here provides a new technique to facilitate future work aiming to assess the clinical efficacy of these putative biomarkers for noninvasive assessment of TBI.
Collapse
Affiliation(s)
- Austin Sigler
- Department of Chemistry, Missouri University of Science and Technology, Rolla, Missouri 65409, United States
| | - Xiaolong He
- Department of Chemistry, Missouri University of Science and Technology, Rolla, Missouri 65409, United States
| | - Mousumi Bose
- Department of Chemistry, Missouri University of Science and Technology, Rolla, Missouri 65409, United States
| | - Alexandre Cristea
- Department of Chemistry, Missouri University of Science and Technology, Rolla, Missouri 65409, United States
| | - Wenyan Liu
- Department of Chemistry, Missouri University of Science and Technology, Rolla, Missouri 65409, United States
| | - Paul Ki-Souk Nam
- Department of Chemistry, Missouri University of Science and Technology, Rolla, Missouri 65409, United States
| | - Donald James
- Phelps Health, Rolla, Missouri 65401, United States
| | - Casey Burton
- Department of Chemistry, Missouri University of Science and Technology, Rolla, Missouri 65409, United States
- Phelps Health, Rolla, Missouri 65401, United States
| | - Honglan Shi
- Department of Chemistry, Missouri University of Science and Technology, Rolla, Missouri 65409, United States
| |
Collapse
|
24
|
Ahmed ME, Selvakumar GP, Kempuraj D, Raikwar SP, Thangavel R, Bazley K, Wu K, Khan O, Khan A, Zaheer S, Iyer S, Burton C, James D, Zaheer A. Glia Maturation Factor (GMF) Regulates Microglial Expression Phenotypes and the Associated Neurological Deficits in a Mouse Model of Traumatic Brain Injury. Mol Neurobiol 2020; 57:4438-4450. [PMID: 32737763 DOI: 10.1007/s12035-020-02040-y] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2020] [Accepted: 07/24/2020] [Indexed: 12/20/2022]
Abstract
Traumatic brain injury (TBI) induces inflammatory responses through microglial activation and polarization towards a more inflammatory state that contributes to the deleterious secondary brain injury. Glia maturation factor (GMF) is a pro-inflammatory protein that is responsible for neuroinflammation following insult to the brain, such as in TBI. We hypothesized that the absence of GMF in GMF-knockout (GMF-KO) mice would regulate microglial activation state and the M1/M2 phenotypes following TBI. We used the weight drop model of TBI in C57BL/6 mice wild-type (WT) and GMF-KO mice. Immunofluorescence staining, Western blot, and ELISA assays were performed to confirm TBI-induced histopathological and neuroinflammatory changes. Behavioral analysis was done to check motor coordination ability and cognitive function. We demonstrated that the deletion of GMF in GMF-KO mice significantly limited lesion volume, attenuated neuronal loss, inhibited gliosis, and activated microglia adopted predominantly anti-inflammatory (M2) phenotypes. Using an ELISA method, we found a gradual decrease in pro-inflammatory cytokines (TNF-α and IL-6) and upregulation of anti-inflammatory cytokines (IL-4 and IL-10) in GMF-KO mice compared with WT mice, thus, promoting the transition of microglia towards a more predominantly anti-inflammatory (M2) phenotype. GMF-KO mice showed significant improvement in motor ability, memory, and cognition. Overall, our results demonstrate that GMF deficiency regulates microglial polarization, which ameliorates neuronal injury and behavioral impairments following TBI in mice and concludes that GMF is a regulator of neuroinflammation and an ideal therapeutic target for the treatment of TBI.
Collapse
Affiliation(s)
- Mohammad Ejaz Ahmed
- Department of Neurology, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA
- Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA
- Harry S. Truman Memorial Veterans Hospital, Columbia, Missouri 65211, USA
| | - Govindhasamy Pushpavathi Selvakumar
- Department of Neurology, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA
- Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA
- Harry S. Truman Memorial Veterans Hospital, Columbia, Missouri 65211, USA
| | - Duraisamy Kempuraj
- Department of Neurology, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA
- Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA
- Harry S. Truman Memorial Veterans Hospital, Columbia, Missouri 65211, USA
| | - Sudhanshu P Raikwar
- Department of Neurology, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA
- Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA
- Harry S. Truman Memorial Veterans Hospital, Columbia, Missouri 65211, USA
| | - Ramasamy Thangavel
- Department of Neurology, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA
- Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA
- Harry S. Truman Memorial Veterans Hospital, Columbia, Missouri 65211, USA
| | - Kieran Bazley
- Department of Neurology, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA
- Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA
| | - Kristopher Wu
- Department of Neurology, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA
- Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA
| | - Osaid Khan
- Department of Neurology, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA
- Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA
| | - Asher Khan
- Department of Neurology, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA
- Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA
| | - Smita Zaheer
- Department of Neurology, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA
- Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA
| | - Shankar Iyer
- Department of Neurology, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA
- Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA
- Harry S. Truman Memorial Veterans Hospital, Columbia, Missouri 65211, USA
| | | | | | - Asgar Zaheer
- Department of Neurology, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA.
- Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA.
- Harry S. Truman Memorial Veterans Hospital, Columbia, Missouri 65211, USA.
| |
Collapse
|
25
|
Kempuraj D, Selvakumar GP, Ahmed ME, Raikwar SP, Thangavel R, Khan A, Zaheer SA, Iyer SS, Burton C, James D, Zaheer A. COVID-19, Mast Cells, Cytokine Storm, Psychological Stress, and Neuroinflammation. Neuroscientist 2020; 26:402-414. [PMID: 32684080 DOI: 10.1177/1073858420941476] [Citation(s) in RCA: 168] [Impact Index Per Article: 42.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new pandemic infectious disease that originated in China. COVID-19 is a global public health emergency of international concern. COVID-19 causes mild to severe illness with high morbidity and mortality, especially in preexisting risk groups. Therapeutic options are now limited to COVID-19. The hallmark of COVID-19 pathogenesis is the cytokine storm with elevated levels of interleukin-6 (IL-6), IL-1β, tumor necrosis factor-alpha (TNF-α), chemokine (C-C-motif) ligand 2 (CCL2), and granulocyte-macrophage colony-stimulating factor (GM-CSF). COVID-19 can cause severe pneumonia, and neurological disorders, including stroke, the damage to the neurovascular unit, blood-brain barrier disruption, high intracranial proinflammatory cytokines, and endothelial cell damage in the brain. Mast cells are innate immune cells and also implicated in adaptive immune response, systemic inflammatory diseases, neuroinflammatory diseases, traumatic brain injury and stroke, and stress disorders. SARS-CoV-2 can activate monocytes/macrophages, dendritic cells, T cells, mast cells, neutrophils, and induce cytokine storm in the lung. COVID-19 can activate mast cells, neurons, glial cells, and endothelial cells. SARS-CoV-2 infection can cause psychological stress and neuroinflammation. In conclusion, COVID-19 can induce mast cell activation, psychological stress, cytokine storm, and neuroinflammation.
Collapse
Affiliation(s)
- Duraisamy Kempuraj
- Department of Neurology, and the Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, MO, USA.,Harry S. Truman Memorial Veterans Hospital, U.S. Department of Veterans Affairs, Columbia, MO, USA
| | - Govindhasamy Pushpavathi Selvakumar
- Department of Neurology, and the Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, MO, USA.,Harry S. Truman Memorial Veterans Hospital, U.S. Department of Veterans Affairs, Columbia, MO, USA
| | - Mohammad Ejaz Ahmed
- Department of Neurology, and the Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, MO, USA.,Harry S. Truman Memorial Veterans Hospital, U.S. Department of Veterans Affairs, Columbia, MO, USA
| | - Sudhanshu P Raikwar
- Department of Neurology, and the Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, MO, USA.,Harry S. Truman Memorial Veterans Hospital, U.S. Department of Veterans Affairs, Columbia, MO, USA
| | - Ramasamy Thangavel
- Department of Neurology, and the Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, MO, USA.,Harry S. Truman Memorial Veterans Hospital, U.S. Department of Veterans Affairs, Columbia, MO, USA
| | - Asher Khan
- Department of Neurology, and the Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, MO, USA
| | - Smita A Zaheer
- Department of Neurology, and the Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, MO, USA
| | - Shankar S Iyer
- Department of Neurology, and the Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, MO, USA.,Harry S. Truman Memorial Veterans Hospital, U.S. Department of Veterans Affairs, Columbia, MO, USA
| | | | | | - Asgar Zaheer
- Department of Neurology, and the Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, MO, USA.,Harry S. Truman Memorial Veterans Hospital, U.S. Department of Veterans Affairs, Columbia, MO, USA
| |
Collapse
|
26
|
Selvakumar GP, Ahmed ME, Iyer SS, Thangavel R, Kempuraj D, Raikwar SP, Bazley K, Wu K, Khan A, Kukulka K, Bussinger B, Zaheer S, Burton C, James D, Zaheer A. Absence of Glia Maturation Factor Protects from Axonal Injury and Motor Behavioral Impairments after Traumatic Brain Injury. Exp Neurobiol 2020; 29:230-248. [PMID: 32565489 PMCID: PMC7344375 DOI: 10.5607/en20017] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2020] [Revised: 06/09/2020] [Accepted: 06/09/2020] [Indexed: 12/11/2022] Open
Abstract
Traumatic brain injury (TBI) causes disability and death, accelerating the progression towards Alzheimer's disease and Parkinson's disease (PD). TBI causes serious motor and cognitive impairments, as seen in PD that arise during the period of the initial insult. However, this has been understudied relative to TBI induced neuroinflammation, motor and cognitive decline that progress towards PD. Neuronal ubiquitin-C-terminal hydrolase- L1 (UCHL1) is a thiol protease that breaks down ubiquitinated proteins and its level represents the severity of TBI. Previously, we demonstrated the molecular action of glia maturation factor (GMF); a proinflammatory protein in mediating neuroinflammation and neuronal loss. Here, we show that the weight drop method induced TBI neuropathology using behavioral tests, western blotting, and immunofluorescence techniques on sections from wild type (WT) and GMF-deficient (GMF-KO) mice. Results reveal a significant improvement in substantia nigral tyrosine hydroxylase and dopamine transporter expression with motor behavioral performance in GMF-KO mice following TBI. In addition, a significant reduction in neuroinflammation was manifested, as shown by activation of nuclear factor-kB, reduced levels of inducible nitric oxide synthase, and cyclooxygenase- 2 expressions. Likewise, neurotrophins including brain-derived neurotrophic factor and glial-derived neurotrophic factor were significantly improved in GMF-KO mice than WT 72 h post-TBI. Consistently, we found that TBI enhances GFAP and UCHL-1 expression and reduces the number of dopaminergic TH-positive neurons in WT compared to GMF-KO mice 72 h post-TBI. Interestingly, we observed a reduction of THpositive tanycytes in the median eminence of WT than GMF-KO mice. Overall, we found that absence of GMF significantly reversed these neuropathological events and improved behavioral outcome. This study provides evidence that PD-associated pathology progression can be initiated upon induction of TBI.
Collapse
Affiliation(s)
- Govindhasamy Pushpavathi Selvakumar
- Harry S. Truman Memorial Veterans Hospital, Columbia, Missouri 65211, USA.,Department of Neurology, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA.,Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA
| | - Mohammad Ejaz Ahmed
- Harry S. Truman Memorial Veterans Hospital, Columbia, Missouri 65211, USA.,Department of Neurology, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA.,Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA
| | - Shankar S Iyer
- Harry S. Truman Memorial Veterans Hospital, Columbia, Missouri 65211, USA.,Department of Neurology, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA.,Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA
| | - Ramasamy Thangavel
- Harry S. Truman Memorial Veterans Hospital, Columbia, Missouri 65211, USA.,Department of Neurology, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA.,Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA
| | - Duraisamy Kempuraj
- Harry S. Truman Memorial Veterans Hospital, Columbia, Missouri 65211, USA.,Department of Neurology, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA.,Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA
| | - Sudhanshu P Raikwar
- Harry S. Truman Memorial Veterans Hospital, Columbia, Missouri 65211, USA.,Department of Neurology, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA.,Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA
| | - Kieran Bazley
- Department of Neurology, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA.,Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA
| | - Kristopher Wu
- Department of Neurology, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA.,Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA
| | - Asher Khan
- Department of Neurology, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA.,Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA
| | - Klaudia Kukulka
- Department of Neurology, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA.,Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA
| | - Bret Bussinger
- Department of Neurology, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA.,Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA
| | - Smita Zaheer
- Department of Neurology, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA.,Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA
| | | | | | - Asgar Zaheer
- Harry S. Truman Memorial Veterans Hospital, Columbia, Missouri 65211, USA.,Department of Neurology, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA.,Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, Missouri 65211, USA
| |
Collapse
|
27
|
Kempuraj D, Ahmed ME, Selvakumar GP, Thangavel R, Raikwar SP, Zaheer SA, Iyer SS, Burton C, James D, Zaheer A. Psychological Stress-Induced Immune Response and Risk of Alzheimer's Disease in Veterans from Operation Enduring Freedom and Operation Iraqi Freedom. Clin Ther 2020; 42:974-982. [PMID: 32184013 PMCID: PMC7308186 DOI: 10.1016/j.clinthera.2020.02.018] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2020] [Revised: 02/19/2020] [Accepted: 02/22/2020] [Indexed: 12/26/2022]
Abstract
PURPOSE Psychological stress is a significant health problem in veterans and their family members. Traumatic brain injury (TBI) and stress lead to the onset, progression, and worsening of several inflammatory and neurodegenerative diseases in veterans and civilians. Alzheimer's disease (AD) is a progressive, irreversible neuroinflammatory disease that causes problems with memory, thinking, and behavior. TBIs and chronic psychological stress cause and accelerate the pathology of neuroinflammatory diseases such as AD. However, the precise molecular and cellular mechanisms governing neuroinflammation and neurodegeneration are currently unknown, especially in veterans. The purpose of this review article was to advance the hypothesis that stress and TBI-mediated immune response substantially contribute and accelerate the pathogenesis of AD in veterans and their close family members and civilians. METHODS The information in this article was collected and interpreted from published articles in PubMed between 1985 and 2020 using the key words stress, psychological stress, Afghanistan war, Operation Enduring Freedom (OEF), Iraq War, Operation Iraqi Freedom (OIF), Operation New Dawn (OND), traumatic brain injury, mast cell and stress, stress and neuroimmune response, stress and Alzheimer's disease, traumatic brain injury, and Alzheimer's disease. FINDINGS Chronic psychological stress and brain injury induce the generation and accumulation of beta-amyloid peptide, amyloid plaques, neurofibrillary tangles, and phosphorylation of tau in the brain, thereby contributing to AD pathogenesis. Active military personnel and veterans are under enormous psychological stress due to various war-related activities, including TBIs, disabilities, fear, new environmental conditions, lack of normal life activities, insufficient communications, explosions, military-related noise, and health hazards. Brain injury, stress, mast cell, and other immune cell activation can induce headache, migraine, dementia, and upregulate neuroinflammation and neurodegeneration in veterans of Operation Enduring Freedom, Operation Iraqi Freedom, and Operation New Dawn. TBIs, posttraumatic stress disorder, psychological stress, pain, glial activation, and dementia in active military personnel, veterans, or their family members can cause AD several years later in their lives. We suggest that there are increasing numbers of veterans with TBIs and stress and that these veterans may develop AD late in life if no appropriate therapeutic intervention is available. IMPLICATIONS Per these published reports, the fact that TBIs and psychological stress can accelerate the pathogenesis of AD should be recognized. Active military personnel, veterans, and their close family members should be evaluated regularly for stress symptoms to prevent the pathogenesis of neurodegenerative diseases, including AD.
Collapse
Affiliation(s)
- Duraisamy Kempuraj
- Harry S. Truman Memorial Veterans Hospital, US Department of Veterans Affairs, Columbia, MO, USA; Department of Neurology, School of Medicine, University of Missouri, Columbia, MO, USA; Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, MO, USA.
| | - Mohammad Ejaz Ahmed
- Harry S. Truman Memorial Veterans Hospital, US Department of Veterans Affairs, Columbia, MO, USA; Department of Neurology, School of Medicine, University of Missouri, Columbia, MO, USA; Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, MO, USA
| | - Govindhasamy Pushpavathi Selvakumar
- Harry S. Truman Memorial Veterans Hospital, US Department of Veterans Affairs, Columbia, MO, USA; Department of Neurology, School of Medicine, University of Missouri, Columbia, MO, USA; Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, MO, USA
| | - Ramasamy Thangavel
- Harry S. Truman Memorial Veterans Hospital, US Department of Veterans Affairs, Columbia, MO, USA; Department of Neurology, School of Medicine, University of Missouri, Columbia, MO, USA; Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, MO, USA
| | - Sudhanshu P Raikwar
- Harry S. Truman Memorial Veterans Hospital, US Department of Veterans Affairs, Columbia, MO, USA; Department of Neurology, School of Medicine, University of Missouri, Columbia, MO, USA; Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, MO, USA
| | - Smita A Zaheer
- Department of Neurology, School of Medicine, University of Missouri, Columbia, MO, USA; Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, MO, USA
| | - Shankar S Iyer
- Harry S. Truman Memorial Veterans Hospital, US Department of Veterans Affairs, Columbia, MO, USA; Department of Neurology, School of Medicine, University of Missouri, Columbia, MO, USA; Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, MO, USA
| | | | | | - Asgar Zaheer
- Harry S. Truman Memorial Veterans Hospital, US Department of Veterans Affairs, Columbia, MO, USA; Department of Neurology, School of Medicine, University of Missouri, Columbia, MO, USA; Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, MO, USA.
| |
Collapse
|
28
|
Sackley CM, Rick C, Au P, Brady MC, Beaton G, Burton C, Caulfield M, Dickson S, Dowling F, Hughes M, Ives N, Jowett S, Masterson-Algar P, Nicoll A, Patel S, Smith CH, Woolley R, Clarke CE. A multicentre, randomised controlled trial to compare the clinical and cost-effectiveness of Lee Silverman Voice Treatment versus standard NHS Speech and Language Therapy versus control in Parkinson's disease: a study protocol for a randomised controlled trial. Trials 2020; 21:436. [PMID: 32460885 PMCID: PMC7251680 DOI: 10.1186/s13063-020-04354-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2020] [Accepted: 04/27/2020] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND Parkinson's disease (PD) affects approximately 145,519 people in the UK. Speech impairments are common with a reported prevalence of 68%, which increase physical and mental demands during conversation, reliance on family and/or carers, and the likelihood of social withdrawal reducing quality of life. In the UK, two approaches to Speech and Language Therapy (SLT) intervention are commonly available: National Health Service (NHS) SLT or Lee Silverman Voice Treatment (LSVT LOUD®). NHS SLT is tailored to the individuals' needs per local practice typically consisting of six to eight weekly sessions; LSVT LOUD® comprises 16 sessions of individual treatment with home-based practice over 4 weeks. The evidence-base for their effectiveness is inconclusive. METHODS/DESIGN PD COMM is a phase III, multicentre, three-arm, unblinded, randomised controlled trial. Five hundred and forty-six people with idiopathic PD, reporting speech or voice problems will be enrolled. We will exclude those with a diagnosis of dementia, laryngeal pathology or those who have received SLT for speech problems in the previous 2 years. Following informed consent and completion of baseline assessments, participants will be randomised in a 1:1:1 ratio to no-intervention control, NHS SLT or LSVT LOUD® via a central computer-generated programme, using a minimisation procedure with a random element, to ensure allocation concealment. Participants randomised to the intervention groups will start treatment within 4 (NHS SLT) or 7 (LSVT LOUD®) weeks of randomisation. PRIMARY OUTCOME Voice Handicap Index (VHI) total score at 3 months. Secondary outcomes include: VHI subscales, Parkinson's Disease Questionnaire-39; Questionnaire on Acquired Speech Disorders; EuroQol-5D-5 L; ICECAP-O; resource utilisation; adverse events and carer quality of life. Mixed-methods process and health economic evaluations will take place alongside the trial. Assessments will be completed before randomisation and at 3, 6 and 12 months after randomisation. The trial started in December 2015 and will run for 77 months. Recruitment will take place in approximately 42 sites around the UK. DISCUSSION The trial will test the hypothesis that SLT is effective for the treatment of speech or voice problems in people with PD compared to no SLT. It will further test whether NHS SLT or LSVT LOUD® provide greater benefit and determine the cost-effectiveness of both interventions. TRIAL REGISTRATION International Standard Randomised Controlled Trials Number (ISRCTN) Registry, ID: 12421382. Registered on 18 April 2016.
Collapse
Affiliation(s)
- C. M. Sackley
- Population Health Sciences, Addison House, King’s College London, Guy’s Campus, London, SE1 1UL UK
- School of Health Science, University of Nottingham, QMC, Nottingham, NG7 2HA UK
| | - C. Rick
- Nottingham Clinical Trials Unit, University of Nottingham, Building 42, University Park, Nottingham, NG7 2RD UK
- Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, B15 2TT UK
| | - P. Au
- Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, B15 2TT UK
| | - M. C. Brady
- NMAHP Research Unit, Glasgow Caledonian University, Glasgow, G4 0BA UK
| | - G. Beaton
- Queen Elizabeth Hospital, NHS Greater Glasgow and Clyde, Glasgow, UK
| | - C. Burton
- School of Allied and Public Health Professions, Canterbury Christ church University, Canterbury, CT1 1QU UK
| | - M. Caulfield
- Bangor Institute for Health and Medical Research, School of Healthcare Sciences, Bangor University, Bangor, UK
| | - S. Dickson
- NMAHP Research Unit, Glasgow Caledonian University, Glasgow, G4 0BA UK
| | - F. Dowling
- Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ UK
| | - M. Hughes
- Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, B15 2TT UK
| | - N. Ives
- Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, B15 2TT UK
| | - S. Jowett
- Health Economics, University of Birmingham, Birmingham,, B15 2TT UK
| | - P. Masterson-Algar
- Bangor Institute for Health and Medical Research, School of Healthcare Sciences, Bangor University, Bangor, UK
| | - A. Nicoll
- NMAHP Research Unit, Glasgow Caledonian University, Glasgow, G4 0BA UK
| | - S. Patel
- Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, B15 2TT UK
| | - C. H. Smith
- Division of Psychology and Language Science, Faculty of Brain Sciences, University College London, London, UK
| | - R. Woolley
- Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, B15 2TT UK
| | - C. E. Clarke
- Institute for Applied Health Research, University of Birmingham, Birmingham, B15 2TT UK
- Department of Neurology, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham,, B18 7QH UK
| |
Collapse
|
29
|
McMillan AK, Phillips EH, Kirkwood AA, Barrans S, Burton C, Rule S, Patmore R, Pettengell R, Ardeshna KM, Lawrie A, Montoto S, Paneesha S, Clifton-Hadley L, Linch DC. Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3-5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial. Ann Oncol 2020; 31:1251-1259. [PMID: 32464282 PMCID: PMC7487775 DOI: 10.1016/j.annonc.2020.05.016] [Citation(s) in RCA: 33] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2020] [Revised: 05/05/2020] [Accepted: 05/07/2020] [Indexed: 12/28/2022] Open
Abstract
Background Outcomes for patients with high-risk diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP chemotherapy are suboptimal but, to date, no alternative regimen has been shown to improve survival rates. This phase 2 trial aimed to assess the efficacy of a Burkitt-like approach for high-risk DLBCL using the dose-intense R-CODOX-M/R-IVAC regimen. Patients and methods Eligible patients were aged 18–65 years with stage II–IV untreated DLBCL and an International Prognostic Index (IPI) score of 3–5. Patients received alternating cycles of CODOX-M (cyclophosphamide, vincristine, doxorubicin and high-dose methotrexate) alternating with IVAC chemotherapy (ifosfamide, etoposide and high-dose cytarabine) plus eight doses of rituximab. Response was assessed by computed tomography after completing all four cycles of chemotherapy. The primary end point was 2-year progression-free survival (PFS). Results A total of 111 eligible patients were registered; median age was 50 years, IPI score was 3 (60.4%) or 4/5 (39.6%), 54% had a performance status ≥2 and 9% had central nervous system involvement. A total of 85 patients (76.6%) completed all four cycles of chemotherapy. There were five treatment-related deaths (4.3%), all in patients with performance status of 3 and aged >50 years. Two-year PFS for the whole cohort was 67.9% [90% confidence interval (CI) 59.9–74.6] and 2-year overall survival was 76.0% (90% CI 68.5–82.0). The ability to tolerate and complete treatment was lower in patients with performance status ≥2 who were aged >50 years, where 2-year PFS was 43.5% (90% CI 27.9–58.0). Conclusions This trial demonstrates that R-CODOX-M/R-IVAC is a feasible and effective regimen for the treatment of younger and/or fit patients with high-risk DLBCL. These encouraging survival rates demonstrate that this regimen warrants further investigation against standard of care. Trial Registration ClinicalTrials.gov (NCT00974792) and EudraCT (2005-003479-19). R-CODOX-M/R-IVAC is an effective regimen for treatment of high-risk DLBCL and high-grade B-cell lymphoma (IPI score 3–5). Treatment was well tolerated in patients aged <50 years, or aged 50–65 with performance status 0 or 1. The 2-year PFS was 67.9% (90% CI: 59.9–74.6) for the whole cohort. This regimen warrants further evaluation against standard of care in high-risk DLBCL.
Collapse
Affiliation(s)
- A K McMillan
- Haematology Department, Nottingham University Hospitals NHS Trust, Nottingham, UK.
| | - E H Phillips
- Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, University College London, London, UK; Division of Cancer Sciences, University of Manchester and The Christie Hospital NHS Trust, Manchester, UK
| | - A A Kirkwood
- Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, University College London, London, UK
| | - S Barrans
- HMDS, St James' University Hospital, Leeds, UK
| | - C Burton
- HMDS, St James' University Hospital, Leeds, UK
| | - S Rule
- Plymouth University Medical School, Plymouth, UK
| | - R Patmore
- Haematology Department, Castle Hill Hospital, Hull, UK
| | - R Pettengell
- Clinical Sciences, St George's University of London, London, UK
| | - K M Ardeshna
- Haematology Department, University College Hospital London, London, UK
| | - A Lawrie
- Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, University College London, London, UK
| | - S Montoto
- Centre for Haemato-oncology, Barts Health NHS Trust, London, UK
| | - S Paneesha
- Haematology Department, Heart of England NHS Trust, Birmingham, UK
| | - L Clifton-Hadley
- Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, University College London, London, UK
| | - D C Linch
- Haematology Department, University College Hospital London, London, UK; UCL Cancer Institute, University College London, UK
| |
Collapse
|
30
|
Ahmed ME, Selvakumar GP, Kempuraj D, Raikwar SP, Thangavel R, Bazley K, Wu K, Khan O, Kukulka K, Bussinger B, Dubova I, Zaheer S, Govindarajan R, Iyer S, Burton C, James D, Zaheer A. Neuroinflammation Mediated by Glia Maturation Factor Exacerbates Neuronal Injury in an in vitro Model of Traumatic Brain Injury. J Neurotrauma 2020; 37:1645-1655. [PMID: 32200671 DOI: 10.1089/neu.2019.6932] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
Traumatic brain injury (TBI) is the primary cause of death and disability affecting over 10 million people in the industrialized world. TBI causes a wide spectrum of secondary molecular and cellular complications in the brain. However, the pathological events are still not yet fully understood. Previously, we have shown that the glia maturation factor (GMF) is a mediator of neuroinflammation in neurodegenerative diseases. To identify the potential molecular pathways accompanying TBI, we used an in vitro cell culture model of TBI. A standardized injury was induced by scalpel cut through a mixed primary cell culture of astrocytes, microglia and neurons obtained from both wild type (WT) and GMF-deficient (GMF-KO) mice. Cell culture medium and whole-cell lysates were collected at 24, 48, and 72 h after the scalpel cuts injury and probed for oxidative stress using immunofluorescence analysis. Results showed that oxidative stress markers such as glutathione and glutathione peroxidase were significantly reduced, while release of cytosolic enzyme lactate dehydrogenase along with nitric oxide and prostaglandin E2 were significantly increased in injured WT cells compared with injured GMF-KO cells. In addition, injured WT cells showed increased levels of oxidation product 4-hydroxynonenal and 8-oxo-2'-deoxyguanosine compared with injured GMF-KO cells. Further, we found that injured WT cells showed a significantly increased expression of glial fibrillary acidic protein, ionized calcium binding adaptor molecule 1, and phosphorylated ezrin/radixin/moesin proteins, and reduced microtubule associated protein expression compared with injured GMF-KO cells after injury. Collectively, our results demonstrate that GMF exacerbates the oxidative stress-mediated neuroinflammation that could be brought about by TBI-induced astroglial activation.
Collapse
Affiliation(s)
- Mohammad Ejaz Ahmed
- Department of Neurology and School of Medicine, University of Missouri, Columbia, Missouri, USA.,Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, Missouri, USA.,Harry S Truman Memorial Veterans Hospital, Columbia, Missouri, USA
| | - Govindhasamy Pushpavathi Selvakumar
- Department of Neurology and School of Medicine, University of Missouri, Columbia, Missouri, USA.,Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, Missouri, USA.,Harry S Truman Memorial Veterans Hospital, Columbia, Missouri, USA
| | - Duraisamy Kempuraj
- Department of Neurology and School of Medicine, University of Missouri, Columbia, Missouri, USA.,Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, Missouri, USA.,Harry S Truman Memorial Veterans Hospital, Columbia, Missouri, USA
| | - Sudhanshu P Raikwar
- Department of Neurology and School of Medicine, University of Missouri, Columbia, Missouri, USA.,Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, Missouri, USA.,Harry S Truman Memorial Veterans Hospital, Columbia, Missouri, USA
| | - Ramasamy Thangavel
- Department of Neurology and School of Medicine, University of Missouri, Columbia, Missouri, USA.,Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, Missouri, USA.,Harry S Truman Memorial Veterans Hospital, Columbia, Missouri, USA
| | - Kieran Bazley
- Department of Neurology and School of Medicine, University of Missouri, Columbia, Missouri, USA.,Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, Missouri, USA
| | - Kristopher Wu
- Department of Neurology and School of Medicine, University of Missouri, Columbia, Missouri, USA.,Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, Missouri, USA
| | - Osaid Khan
- Department of Neurology and School of Medicine, University of Missouri, Columbia, Missouri, USA.,Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, Missouri, USA
| | - Klaudia Kukulka
- Department of Neurology and School of Medicine, University of Missouri, Columbia, Missouri, USA.,Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, Missouri, USA
| | - Bret Bussinger
- Department of Neurology and School of Medicine, University of Missouri, Columbia, Missouri, USA.,Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, Missouri, USA
| | - Iuliia Dubova
- Department of Neurology and School of Medicine, University of Missouri, Columbia, Missouri, USA.,Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, Missouri, USA.,Harry S Truman Memorial Veterans Hospital, Columbia, Missouri, USA
| | - Smita Zaheer
- Department of Neurology and School of Medicine, University of Missouri, Columbia, Missouri, USA.,Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, Missouri, USA
| | - Raghav Govindarajan
- Department of Neurology and School of Medicine, University of Missouri, Columbia, Missouri, USA.,Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, Missouri, USA
| | - Shankar Iyer
- Department of Neurology and School of Medicine, University of Missouri, Columbia, Missouri, USA.,Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, Missouri, USA.,Harry S Truman Memorial Veterans Hospital, Columbia, Missouri, USA
| | | | | | - Asgar Zaheer
- Department of Neurology and School of Medicine, University of Missouri, Columbia, Missouri, USA.,Center for Translational Neuroscience, School of Medicine, University of Missouri, Columbia, Missouri, USA.,Harry S Truman Memorial Veterans Hospital, Columbia, Missouri, USA
| |
Collapse
|
31
|
Hutchison M, Gittins J, Walker A, Moore A, Burton C, Sparks N. Washing table eggs: a review of the scientific and engineering issues. WORLD POULTRY SCI J 2019. [DOI: 10.1079/wps20030015] [Citation(s) in RCA: 39] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- M.L. Hutchison
- ADAS Microbiology Department, Woodthorne, Wergs Road, Wolverhampton. WV6 8QT, United Kingdom
| | - J. Gittins
- ADAS Poultry Team, Woodthorne, Wergs Road, Wolverhampton, WV6 8QT, United Kingdom
| | - A. Walker
- ADAS Gleadthorpe, Meden Vale, Mansfield, Notts. NG20 9PD, United Kingdom
| | - A. Moore
- ADAS Microbiology Department, Woodthorne, Wergs Road, Wolverhampton. WV6 8QT, United Kingdom
| | - C. Burton
- Silsoe Research Institute, Wrest Park, Silsoe MK45 4HS, United Kingdom
| | - N. Sparks
- Avian Science Research Centre, SAC, Ayr, KA6 5HW, United Kingdom
| |
Collapse
|
32
|
Burton C, Tso I, Hampstead B, Taylor S. B-04 Combining tDCS and Cognitive Training for People with Severe Mental Illness: Preliminary Feasibility and Acceptability Findings. Arch Clin Neuropsychol 2019. [DOI: 10.1093/arclin/acz034.87] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Objective
Technological advances in neuromodulation and cognitive remediation provide opportunities to develop novel interventions, though a critical first determination is whether such treatments are feasible and acceptable to participants. This study evaluated a combined transcranial direct current stimulation (tDCS) and computerized cognitive training intervention for individuals with severe mental illness; we examined participant recruitment, retention, and adherence to the interventions, along with qualitative feedback.
Method
Participants included adults with schizophrenia-spectrum or bipolar disorder and impaired working memory (performance ≤1 standard deviation below average of healthy individuals on a spatial span or letter-number span test). In this randomized crossover study, all participants received the combined intervention (ten tDCS sessions in the clinic concurrent with cognitive training), and ten hours of at-home training, and completed neuropsychological and clinical assessments at three time points.
Results
To date, thirteen participants provided informed consent. Seven participants were screened out; five exceeded the cognitive cutoff and one did not meet the diagnostic criterion. No remaining participants have withdrawn prior to study completion. Four participants completed all tDCS sessions, and one completed 80%. No tDCS session has been discontinued. At-home training has proven more challenging; only one participant completed all ten hours, and three did not complete any at all. Participant feedback has been positive; all expressed satisfaction with both treatments though some said symptoms or busy schedules interfered with at-home training.
Conclusions
Combining tDCS with computerized cognitive training appears feasible and acceptable. Strategic recruitment efforts to capture those with cognitive impairment appears necessary, as well as troubleshooting barriers to at-home training.
Collapse
|
33
|
Cummin T, Caddy J, Mercer K, Maishman T, Schuh A, Lopez Pascua L, Collins G, McMillan A, Ardeshna K, Galanopoulous A, Burton C, Barrans S, Griffiths G, Johnson P, Davies A. ACCEPT: A PHASE IB/II COMBINATION OF ACALABRUTINIB WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISOLONE (R-CHOP) FOR PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL). Hematol Oncol 2019. [DOI: 10.1002/hon.39_2629] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- T.E. Cummin
- Southampton Cancer Research UK (CRUK) Centre/CRUK Southampton Clinical Trials Unit/CRUK Experimental Cancer Medicines Centre UK/ Southampton CRUK Clinical Trials Unit; University of Southampton; Southampton United Kingdom
| | - J. Caddy
- Southampton Cancer Research UK (CRUK) Centre/CRUK Southampton Clinical Trials Unit/CRUK Experimental Cancer Medicines Centre UK/ Southampton CRUK Clinical Trials Unit; University of Southampton; Southampton United Kingdom
| | - K. Mercer
- Southampton Cancer Research UK (CRUK) Centre/CRUK Southampton Clinical Trials Unit/CRUK Experimental Cancer Medicines Centre UK/ Southampton CRUK Clinical Trials Unit; University of Southampton; Southampton United Kingdom
| | - T. Maishman
- Southampton Cancer Research UK (CRUK) Centre/CRUK Southampton Clinical Trials Unit/CRUK Experimental Cancer Medicines Centre UK/ Southampton CRUK Clinical Trials Unit; University of Southampton; Southampton United Kingdom
| | - A. Schuh
- Oxford Molecular Diagnostics Centre; University of Oxford; Oxford United Kingdom
| | - L. Lopez Pascua
- Oxford Molecular Diagnostics Centre; University of Oxford; Oxford United Kingdom
| | - G. Collins
- Lymphoma Service; Oxford Univeristy Hospitals; Oxford United Kingdom
| | - A. McMillan
- Department of Haematology; Nottingham University Hospitals NHS Trust; Nottingham United Kingdom
| | - K. Ardeshna
- Department of Haematology; Univeristy College Hospitals London; London United Kingdom
| | - A. Galanopoulous
- Southampton Cancer Research UK (CRUK) Centre/CRUK Southampton Clinical Trials Unit/CRUK Experimental Cancer Medicines Centre UK/ Southampton CRUK Clinical Trials Unit; University of Southampton; Southampton United Kingdom
| | - C. Burton
- Haematological Malignancies Diagnostic Service; Leeds Cancer Centre; Leeds United Kingdom
| | - S. Barrans
- Haematological Malignancies Diagnostic Service; Leeds Cancer Centre; Leeds United Kingdom
| | - G. Griffiths
- Southampton Cancer Research UK (CRUK) Centre/CRUK Southampton Clinical Trials Unit/CRUK Experimental Cancer Medicines Centre UK/ Southampton CRUK Clinical Trials Unit; University of Southampton; Southampton United Kingdom
| | - P. Johnson
- Southampton Cancer Research UK (CRUK) Centre/CRUK Southampton Clinical Trials Unit/CRUK Experimental Cancer Medicines Centre UK/ Southampton CRUK Clinical Trials Unit; University of Southampton; Southampton United Kingdom
| | - A.J. Davies
- Southampton Cancer Research UK (CRUK) Centre/CRUK Southampton Clinical Trials Unit/CRUK Experimental Cancer Medicines Centre UK/ Southampton CRUK Clinical Trials Unit; University of Southampton; Southampton United Kingdom
| |
Collapse
|
34
|
Barrans S, Painter D, van Hoppe S, Smith A, Sha C, Cucco F, Du M, Westhead D, Davies A, Johnson P, Roman E, Burton C. DEFINING BURKITT-LIKE LYMPHOMA WITH 11Q ABERRATION IN A SPECIALISED UK HAEMATOPATHOLOGY DIAGNOSTIC SERVICE. Hematol Oncol 2019. [DOI: 10.1002/hon.101_2629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- S. Barrans
- HMDS; Leeds Cancer Centre; Leeds United Kingdom
| | - D. Painter
- ECSG; Health Sciences, University of York; York United Kingdom
| | | | - A. Smith
- ECSG; Health Sciences, University of York; York United Kingdom
| | - C. Sha
- School of Molecular and Cellular Biology (Faculty of Biological Sciences); University of Leeds; Leeds United Kingdom
| | - F. Cucco
- Department of Pathology; University of Cambridge; Cambridge United Kingdom
| | - M. Du
- Department of Pathology; University of Cambridge; Cambridge United Kingdom
| | - D. Westhead
- School of Molecular and Cellular Biology (Faculty of Biological Sciences); University of Leeds; Leeds United Kingdom
| | - A. Davies
- Faculty of Medicine; University of Southampton; Southampton United Kingdom
| | - P. Johnson
- Faculty of Medicine; University of Southampton; Southampton United Kingdom
| | - E. Roman
- ECSG; Health Sciences, University of York; York United Kingdom
| | - C. Burton
- HMDS; Leeds Cancer Centre; Leeds United Kingdom
| |
Collapse
|
35
|
Cummin T, Cox K, Murray T, Barrans S, Sha C, Westhead D, Burton C, Davies A, Cragg M, Johnson P, Carter M. HIGH EXPRESSION OF BCL-2 AND BCL-XL IN DIFFUSE LARGE B-CELL LYMPHOMA CONFER POOR PROGNOSIS BUT MAY BE REVERSIBLE BY COMBINED INHIBITION WITH BET INHIBITORS AND BH3 MIMETICS. Hematol Oncol 2019. [DOI: 10.1002/hon.84_2629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- T.E. Cummin
- Cancer Sciences; University of Southampton; Southampton United Kingdom
| | - K. Cox
- Cancer Sciences; University of Southampton; Southampton United Kingdom
| | - T. Murray
- Cancer Sciences; University of Southampton; Southampton United Kingdom
| | - S. Barrans
- Haematalogical Malignancies Diagnostic Service; University of Leeds; Leeds United Kingdom
| | - C. Sha
- Faculty of Biological Sciences; University of Leeds; Leeds United Kingdom
| | - D. Westhead
- Faculty of Biological Sciences; University of Leeds; Leeds United Kingdom
| | - C. Burton
- Haematalogical Malignancies Diagnostic Service; University of Leeds; Leeds United Kingdom
| | - A. Davies
- Southampton Clinical Trials Unit; University of Southampton; Southampton United Kingdom
| | - M. Cragg
- Cancer Sciences; University of Southampton; Southampton United Kingdom
| | - P. Johnson
- Cancer Sciences; University of Southampton; Southampton United Kingdom
| | - M. Carter
- Cancer Sciences; University of Southampton; Southampton United Kingdom
| |
Collapse
|
36
|
Davies A, Tansley Hancock O, Cummin T, Caddy J, Stanton L, Burton C, Barrans S, Coleman A, Osborne W, McKay P, Griffiths G, Johnson P. ARGO: A RANDOMISED PHASE II STUDY OF ATEZOLIZUMAB WITH RITUXIMAB, GEMCITABINE AND OXALIPLATIN IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA WHO ARE NOT CANDIDATES FOR HIGH-DOSE THERAPY. Hematol Oncol 2019. [DOI: 10.1002/hon.1_2632] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- A.J. Davies
- Southampton Cancer Research UK (CRUK) Centre/CRUK Southampton Clinical Trials Unit/CRUK Experimental Cancer Medicines Centre UK; University of Southampton; Southampton United Kingdom
| | - O. Tansley Hancock
- Southampton Cancer Research UK (CRUK) Centre/CRUK Southampton Clinical Trials Unit/CRUK Experimental Cancer Medicines Centre UK; University of Southampton; Southampton United Kingdom
| | - T. Cummin
- Southampton Cancer Research UK (CRUK) Centre/CRUK Southampton Clinical Trials Unit/CRUK Experimental Cancer Medicines Centre UK; University of Southampton; Southampton United Kingdom
| | - J. Caddy
- Southampton Cancer Research UK (CRUK) Centre/CRUK Southampton Clinical Trials Unit/CRUK Experimental Cancer Medicines Centre UK; University of Southampton; Southampton United Kingdom
| | - L. Stanton
- Southampton Cancer Research UK (CRUK) Centre/CRUK Southampton Clinical Trials Unit/CRUK Experimental Cancer Medicines Centre UK; University of Southampton; Southampton United Kingdom
| | - C. Burton
- Haematological Malignancies Diagnostic Service; St James's University Hospital; Leeds United Kingdom
| | - S. Barrans
- Haematological Malignancies Diagnostic Service; St James's University Hospital; Leeds United Kingdom
| | - A. Coleman
- Southampton Cancer Research UK (CRUK) Centre/CRUK Southampton Clinical Trials Unit/CRUK Experimental Cancer Medicines Centre UK; University of Southampton; Southampton United Kingdom
| | - W. Osborne
- Freeman Hospital; Newcastle United Kingdom
| | - P. McKay
- Beatson West of Scotland Cancer Centre; Glasgow United Kingdom
| | - G. Griffiths
- Southampton Cancer Research UK (CRUK) Centre/CRUK Southampton Clinical Trials Unit/CRUK Experimental Cancer Medicines Centre UK; University of Southampton; Southampton United Kingdom
| | - P. Johnson
- Southampton Cancer Research UK (CRUK) Centre/CRUK Southampton Clinical Trials Unit/CRUK Experimental Cancer Medicines Centre UK; University of Southampton; Southampton United Kingdom
| |
Collapse
|
37
|
Korfi K, Araf S, Bewicke-Copley F, Kumar E, Cummin T, Ashton-Key M, Barrans S, Van Hoppe S, Burton C, Elshiekh M, Rule S, Crosbie N, Clear A, Calaminici M, Menon G, Sha C, Bentley M, Nagano A, Davies A, Painter D, Smith A, Okosun J, Gribben J, Naresh K, Westhead D, Wang J, Johnson P, Fitzgibbon J. LONGITUDINAL ANALYSES OF DIAGNOSTIC-RELAPSE BIOPSIES OF DIFFUSE LARGE B CELL LYMPHOMA SUGGEST THAT RELAPSE IS MEDIATED BY DISTINCT MECHANISMS IN ABC AND GCB LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.100_2629] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- K. Korfi
- Centre for Haemato-Oncology; Barts Cancer Institute; London United Kingdom
| | - S. Araf
- Centre for Haemato-Oncology; Barts Cancer Institute; London United Kingdom
| | - F. Bewicke-Copley
- Centre for Molecular Oncology; Barts Cancer Institute; London United Kingdom
| | - E. Kumar
- Centre for Haemato-Oncology; Barts Cancer Institute; London United Kingdom
| | - T. Cummin
- Cancer Research UK Centre; University of Southampton; Southampton United Kingdom
| | - M. Ashton-Key
- Cellular Pathology; University Hospital Southampton NHS Foundation Trust; Southampton United Kingdom
| | - S. Barrans
- HMDS; Leeds Teaching Hospitals NHS Trust; Leeds United Kingdom
| | - S. Van Hoppe
- HMDS; Leeds Teaching Hospitals NHS Trust; Leeds United Kingdom
| | - C. Burton
- HMDS; Leeds Teaching Hospitals NHS Trust; Leeds United Kingdom
| | - M. Elshiekh
- Cellular & Molecular Pathology; Imperial College NHS Trust & Imperial College London; London United Kingdom
| | - S. Rule
- Department of Haematology; Derriford Hospital, University of Plymouth; Plymouth United Kingdom
| | - N. Crosbie
- Department of Haematology; University Hospitals Plymouth NHS Trust; Plymouth United Kingdom
| | - A. Clear
- Centre for Haemato-Oncology; Barts Cancer Institute; London United Kingdom
| | - M. Calaminici
- Centre for Haemato-Oncology; Barts Cancer Institute; London United Kingdom
| | - G. Menon
- Haemato-Oncology Diagnostic Service; Liverpool Clinical Laboratories; Liverpool United Kingdom
| | - C. Sha
- School of Molecular and Cellular Biology; University of Leeds; Leeds United Kingdom
| | - M. Bentley
- School of Molecular and Cellular Biology; University of Leeds; Leeds United Kingdom
| | - A. Nagano
- Centre for Molecular Oncology; Barts Cancer Institute; London United Kingdom
| | - A. Davies
- Cancer Research UK Centre; University of Southampton; Southampton United Kingdom
| | - D. Painter
- Epidemiology and Cancer Statistics Group; University of York; York United Kingdom
| | - A. Smith
- Epidemiology and Cancer Statistics Group; University of York; York United Kingdom
| | - J. Okosun
- Centre for Haemato-Oncology; Barts Cancer Institute; London United Kingdom
| | - J. Gribben
- Centre for Haemato-Oncology; Barts Cancer Institute; London United Kingdom
| | - K.N. Naresh
- Cellular & Molecular Pathology; Imperial College NHS Trust & Imperial College London; London United Kingdom
| | - D. Westhead
- School of Molecular and Cellular Biology; University of Leeds; Leeds United Kingdom
| | - J. Wang
- Centre for Molecular Oncology; Barts Cancer Institute; London United Kingdom
| | - P. Johnson
- Cancer Research UK Centre; University of Southampton; Southampton United Kingdom
| | - J. Fitzgibbon
- Centre for Haemato-Oncology; Barts Cancer Institute; London United Kingdom
| |
Collapse
|
38
|
Lim S, Burton C, Barrans S, Kirkwood A, Patrick P, Stevens L, Clifton-Hadley L, Johnson P, Thirdborough S. TRANSCRIPTIONAL NETWORKS ASSOCIATED WITH TREATMENT FAILURE IN ADVANCED-STAGE HODGKIN LYMPHOMA: DATA FROM THE RATHL TRIAL (CRUK/07/033). Hematol Oncol 2019. [DOI: 10.1002/hon.103_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- S.H. Lim
- Centre for Cancer Immunology & CRUK Centre; University of Southampton; Southampton United Kingdom
| | - C. Burton
- HMDS; Leeds Cancer Centre; Leeds United Kingdom
| | - S. Barrans
- HMDS; Leeds Cancer Centre; Leeds United Kingdom
| | - A. Kirkwood
- CR UK & UCL Cancer Trials Centre; UCL Cancer Institute, University College London; London United Kingdom
| | - P. Patrick
- CR UK & UCL Cancer Trials Centre; UCL Cancer Institute, University College London; London United Kingdom
| | - L. Stevens
- CR UK & UCL Cancer Trials Centre; UCL Cancer Institute, University College London; London United Kingdom
| | - L. Clifton-Hadley
- CR UK & UCL Cancer Trials Centre; UCL Cancer Institute, University College London; London United Kingdom
| | - P.W. Johnson
- Centre for Cancer Immunology & CRUK Centre; University of Southampton; Southampton United Kingdom
| | - S.M. Thirdborough
- Centre for Cancer Immunology & CRUK Centre; University of Southampton; Southampton United Kingdom
| |
Collapse
|
39
|
Burton C, Ma Y. Current Trends in Cancer Biomarker Discovery Using Urinary Metabolomics: Achievements and New Challenges. Curr Med Chem 2019; 26:5-28. [PMID: 28914192 DOI: 10.2174/0929867324666170914102236] [Citation(s) in RCA: 33] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2016] [Revised: 07/26/2016] [Accepted: 08/08/2016] [Indexed: 12/20/2022]
Abstract
BACKGROUND The development of effective screening methods for early cancer detection is one of the foremost challenges facing modern cancer research. Urinary metabolomics has recently emerged as a potentially transformative approach to cancer biomarker discovery owing to its noninvasive sampling characteristics and robust analytical feasibility. OBJECTIVE To provide an overview of new developments in urinary metabolomics, cover the most promising aspects of hyphenated techniques in untargeted and targeted metabolomics, and to discuss technical and clinical limitations in addition to the emerging challenges in the field of urinary metabolomics and its application to cancer biomarker discovery. METHODS A systematic review of research conducted in the past five years on the application of urinary metabolomics to cancer biomarker discovery was performed. Given the breadth of this topic, our review focused on the five most widely studied cancers employing urinary metabolomics approaches, including lung, breast, bladder, prostate, and ovarian cancers. RESULTS As an extension of conventional metabolomics, urinary metabolomics has benefitted from recent technological developments in nuclear magnetic resonance, mass spectrometry, gas and liquid chromatography, and capillary electrophoresis that have improved urine metabolome coverage and analytical reproducibility. Extensive metabolic profiling in urine has revealed a significant number of altered metabolic pathways and putative biomarkers, including pteridines, modified nucleosides, and acylcarnitines, that have been associated with cancer development and progression. CONCLUSION Urinary metabolomics presents a transformative new approach toward cancer biomarker discovery with high translational capacity to early cancer screening.
Collapse
Affiliation(s)
- Casey Burton
- Department of Chemistry and Center for Single Nanoparticle, Single Cell, and Single Molecule Monitoring, Missouri University of Science and Technology, Rolla, MO, United States
| | - Yinfa Ma
- Department of Chemistry and Center for Single Nanoparticle, Single Cell, and Single Molecule Monitoring, Missouri University of Science and Technology, Rolla, MO, United States
| |
Collapse
|
40
|
Williams P, Bond CM, Burton C, Murchie P. A systematic review of the use, quality and effects of pelvic examination in primary care for the detection of gynaecological cancer. J OBSTET GYNAECOL 2018; 38:737. [PMID: 29944043 DOI: 10.1080/01443615.2018.1444410] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
AIM This three part systematic review gathered all the current evidence on the use, quality and effects of pelvic examination (abdominal palpation, bimanual vaginal examination ± visualisation of the cervix) in primary care in diagnosing gynaecological cancer. Research questions • Do primary care practitioners perform pelvic examination during the assessment of symptoms, which are potentially indicative of gynaecological cancer? (RQ1) • What is the quality of pelvic examination performed in primary care, in terms of technical competence and interpretation of findings? (RQ2) • Is pelvic examination associated with the referral of patients with gynaecological cancer, and if so, in what way? (RQ3) Methods: PRISMA guidelines were followed. MEDLINE, EMBASE and Cochrane databases were searched using a combination of four terms, their MeSH terms and synonyms: pelvic examination; primary care; competency and gynaecological cancer. Inclusion and exclusion criteria were defined. Citation lists of all identified papers were searched. Two authors (PW and PM or CMB or CB) independently screened titles, abstracts and the full texts of publications. Data extraction was performed by PW and duplicated in all papers by a second reviewer (PM, CMB or CB). Paper quality was assessed using CASP methodology. RESULTS Nine hundred fifty four references were identified: 21 met the inclusion criteria: 5 RQ1; 6 RQ2; 10 RQ3. Examination rates prior to referral were generally low: one paper identified pre-referral PE in 52% of the patients; remaining papers demonstrated examination in less than half of the patients with suspicious symptoms. No papers explored GPs' competence at performing PE directly; but one paper identified 39% of 'clinically suspicious' cervices referred for colposcopy as having no abnormality. Pre-referral PE was associated with reduced diagnostic delay and early stage diagnosis. CONCLUSIONS Pre-referral pelvic examination in symptomatic women appears to be under-performed, despite urgent suspected cancer referral guideline recommendation to do so (Healthcare Improvement Scotland 2014 ; National Institute for Health and Care Excellence 2015 ). While no evidence was found to confirm GPs' competence for performing PE, there was an association with shorter diagnostic delay and better outcomes in those women where it was performed.
Collapse
Affiliation(s)
- P Williams
- a Institute of Applied Health Sciences , University of Aberdeen , Aberdeen , Scotland
| | - C M Bond
- a Institute of Applied Health Sciences , University of Aberdeen , Aberdeen , Scotland
| | - C Burton
- b Academic Unit of Primary Care , University of Sheffield , Sheffield , England
| | - P Murchie
- a Institute of Applied Health Sciences , University of Aberdeen , Aberdeen , Scotland
| |
Collapse
|
41
|
Burton C, Rifai S, Malhi Y. Inter-comparison and assessment of gridded climate products over tropical forests during the 2015/2016 El Niño. Philos Trans R Soc Lond B Biol Sci 2018; 373:20170406. [PMID: 30297471 PMCID: PMC6178435 DOI: 10.1098/rstb.2017.0406] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/25/2018] [Indexed: 11/12/2022] Open
Abstract
To understand the impacts of extreme climate events, it is first necessary to understand the spatio-temporal characteristics of the event. Gridded climate products are frequently used to describe climate patterns but have been shown to perform poorly over data-sparse regions such as tropical forests. Often, they are uncritically employed in a wide range of studies linking tropical forest processes to large-scale climate variability. Here, we conduct an inter-comparison and assessment of near-surface air temperature fields supplied by four state-of-the-art reanalysis products, along with precipitation estimates supplied by four merged satellite-gauge rainfall products. Firstly, spatio-temporal patterns of temperature and precipitation anomalies during the 2015-2016 El Niño are shown for each product to characterize the impact of the El Niño on the tropical forest biomes of Equatorial Africa, Southeast Asia and South America. Using meteorological station data, a two-stage assessment is then conducted to determine which products most reliably model tropical climates during the 2015-2016 El Niño, and which perform best over the longer-term satellite observation period (1980-2016). Results suggest that eastern Amazonia, parts of the Congo Basin and mainland Southeast Asia all experienced significant monthly mean temperature anomalies during the El Niño, while northeastern Amazonia, eastern Borneo and southern New Guinea experienced significant precipitation deficits. Our results suggest ERA-Interim and MERRA2 are the most reliable air temperature datasets, while TRMM 3B42 V7 and CHIRPS v2.0 are the best-performing rainfall datasets.This article is part of a discussion meeting issue 'The impact of the 2015/2016 El Niño on the terrestrial tropical carbon cycle: patterns, mechanisms and implications'.
Collapse
Affiliation(s)
- C Burton
- Environmental Change Institute, School of Geography and the Environment, University of Oxford, South Parks Road, Oxford OX1 3QY, UK
| | - S Rifai
- Environmental Change Institute, School of Geography and the Environment, University of Oxford, South Parks Road, Oxford OX1 3QY, UK
| | - Y Malhi
- Environmental Change Institute, School of Geography and the Environment, University of Oxford, South Parks Road, Oxford OX1 3QY, UK
| |
Collapse
|
42
|
Mitchell K, Webster J, Tuson C, Burton C, Sutton P, Dunn R, Chandrajay D, Narayanan D, Mansfield M, Barth J, Bandyopadhyay A, Haralambos K, Power B, Jessop J. Setting up a regional fh service; a summary of the achievements and challenges. ATHEROSCLEROSIS SUPP 2018. [DOI: 10.1016/j.atherosclerosissup.2018.07.039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
43
|
Brocklehurst PR, Williams L, Burton C, Goodwin T, Rycroft-Malone J. Implementation and trial evidence: a plea for fore-thought. Br Dent J 2018; 222:331-335. [PMID: 28281585 DOI: 10.1038/sj.bdj.2017.213] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/27/2017] [Indexed: 11/09/2022]
Abstract
In a world where evidence-based practice is see as the foundation of modern healthcare, this paper asks when and how should we be accounting for the input of patients, the public, dental professionals, commissioners and policy-makers in the evidence generation process?
Collapse
Affiliation(s)
| | - L Williams
- School of Healthcare Sciences, Bangor University
| | - C Burton
- School of Healthcare Sciences, Bangor University
| | | | - J Rycroft-Malone
- Research &Impact, Bangor Institute of Health and Medical Research, Bangor University
| |
Collapse
|
44
|
Pike L, Kirkwood A, Patrick P, Radford J, Burton C, Stevens L, Clifton-Hadley L, Johnson P, Barrington S. CAN BASELINE PET-CT FEATURES PREDICT OUTCOMES IN ADVANCED HODGKIN LYMPHOMA? A PROSPECTIVE EVALUATION OF UK PATIENTS IN THE RATHL TRIAL (CRUK/07/033). Hematol Oncol 2017. [DOI: 10.1002/hon.2437_18] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- L.C. Pike
- KCL and Guys'& St Thomas' PET Centre; Division of Imaging and Biomedical Engineering, Kings College London; London UK
| | - A.A. Kirkwood
- Cancer Research UK and UCL Cancer Trials Centre; University College London; London UK
| | - P. Patrick
- Cancer Research UK and UCL Cancer Trials Centre; University College London; London UK
| | - J. Radford
- Division of Molecular & Clinical Cancer Sciences; University of Manchester and The Christie NHS Foundation Trust; Manchester UK
| | - C. Burton
- Haematological Malignancy Diagnostic Service; University of Leeds; Leeds
| | - L. Stevens
- Cancer Research UK and UCL Cancer Trials Centre; University College London; London UK
| | - L. Clifton-Hadley
- Cancer Research UK and UCL Cancer Trials Centre; University College London; London UK
| | - P.W. Johnson
- University of Southampton; Cancer Research UK Centre; Southampton UK
| | - S.F. Barrington
- KCL and Guys'& St Thomas' PET Centre; Division of Imaging and Biomedical Engineering, Kings College London; London UK
| |
Collapse
|
45
|
Burton C, Barrans S, Ahmed S, Bentley M, Clipson A, Wang M, Taylor J, Detute R, Westhead D, Care M, Du M, Davies A, Johnson P. CROSS-PLATFORM VALIDATION OF GENE EXPRESSION PROFILING (GEP) BASED CELL OF ORIGIN (COO) CLASSIFICATION IN a CLINICAL LABORATORY SETTING. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_96] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
| | | | - S. Ahmed
- HMDS; Leeds Cancer Centre; Leeds UK
| | - M.A. Bentley
- School of Molecular and Cellular Biology; University of Leeds; Leeds UK
| | - A. Clipson
- Division of Molecular Histopathology; University of Cambridge; Cambridge UK
| | - M. Wang
- Division of Molecular Histopathology; University of Cambridge; Cambridge UK
| | | | | | - D.R. Westhead
- School of Molecular and Cellular Biology; University of Leeds; Leeds UK
| | - M.A. Care
- School of Molecular and Cellular Biology; University of Leeds; Leeds UK
| | - M.Q. Du
- Division of Molecular Histopathology; University of Cambridge; Cambridge UK
| | - A. Davies
- University of Southampton; Cancer Research UK Centre; Southampton UK
| | - P.W. Johnson
- University of Southampton; Cancer Research UK Centre; Southampton UK
| |
Collapse
|
46
|
Chen R, Gibb A, Collins G, Popat R, El-Sharkawi D, Burton C, Lewis D, Miall F, Forgie A, Compagnoni A, Andreola G, Brar S, Thall A, Woolfson A, Radford J. BLOCKADE OF THE PD-1 CHECKPOINT WITH ANTI-PD-L1 ANTIBODY AVELUMAB IS SUFFICIENT FOR CLINICAL ACTIVITY IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (CHL). Hematol Oncol 2017. [DOI: 10.1002/hon.2437_54] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- R. Chen
- Hematology/HCT; City of Hope Medical Center; Duarte USA
| | - A.L. Gibb
- Medical Oncology; The Christie NHS Foundation Trust; Withington, Manchester UK
| | - G.P. Collins
- Clinical Haematology; Oxford University Hospitals; Oxford UK
| | - R. Popat
- NIHR UCLH Clinical Research Facility; University College London Hospitals NHS Trust; London UK
| | - D. El-Sharkawi
- NIHR UCLH Clinical Research Facility; University College London Hospitals NHS Trust; London UK
| | - C. Burton
- Haematology; Leeds Teaching Hospitals NHS Trust; Leeds UK
| | - D. Lewis
- Haematology; Derriford Hospital Plymouth; Plymouth UK
| | - F.M. Miall
- Haematology; University Hospitals Leicester; Leicester UK
| | - A. Forgie
- Oncology; Pfizer Inc.; San Francisco USA
| | | | | | - S. Brar
- Clinical Pharmacology; Pfizer Inc.; La Jolla USA
| | - A. Thall
- Global Product Development; Pfizer Inc; La Jolla USA
| | - A. Woolfson
- Pfizer, Inc.; Senior Director & Global Clinical Leader Early and Late Stage I-O Hematology; New York USA
| | - J. Radford
- Manchester Academic Health Science Centre; University of Manchester and the Christie NHS Foundation Trust; Manchester UK
| |
Collapse
|
47
|
Davies A, Barrans S, Maishman T, Cummin T, Bentley M, Mamot C, Novak U, Caddy J, Hamid D, Kazmi-Stokes S, Mcmillan A, Fields P, Pocock C, Kruger A, Collins G, Sha C, Clipson A, Wang M, Tooze R, Care M, Griffiths G, Du M, Westhead D, Burton C, Jack A, Johnson P. DIFFERENTIAL EFFICACY OF BORTEZOMIB IN SUBTYPES OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBL): a PROSPECTIVE RANDOMISED STUDY STRATIFIED BY TRANSCRIPTOME PROFILING: REMODL-B. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_120] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- A.J. Davies
- Cancer Research UK Centre; University of Southampton (PMAL Consortium); Southampton UK
| | - S. Barrans
- Haematological Malignancy Diagnostic Service, Haematological Malignancy Diagnostic Service; St. James's Institute of Oncology, Leeds; Leeds UK
| | - T. Maishman
- Southampton Clinical Trials Unit; University of Southampton; Southampton UK
| | - T.E. Cummin
- Cancer Research UK Centre; University of Southampton (PMAL Consortium); Southampton UK
| | - M. Bentley
- School of Molecular and Cellular Biology; University of Leeds; Leeds UK
| | - C. Mamot
- Swiss Group for Clinical Cancer Research (SAKK); Kantonsspital Aarau; Bern Switzerland
| | - U. Novak
- Swiss Group for Clinical Cancer Research (SAKK); Inselspital / Bern University Hospital; Bern Switzerland
| | - J. Caddy
- Cancer Research UK Centre; University of Southampton (PMAL Consortium); Southampton UK
| | - D. Hamid
- Southampton Clinical Trials Unit; University of Southampton; Southampton UK
| | - S.H. Kazmi-Stokes
- Cancer Research UK Centre; University of Southampton (PMAL Consortium); Southampton UK
| | - A. Mcmillan
- Haematology; Nottingham City Hospital; Nottingham UK
| | - P.A. Fields
- Haematology; Guy's and St Thomas' and King's College Hospitals; London UK
| | - C. Pocock
- Haematology; East Kent Hospitals University NHS Trust; Canterbury UK
| | - A. Kruger
- Haematology; Royal Cornwall Hospital; Truro UK
| | - G. Collins
- Clinical Haematology; Churchill Hospital; Oxford UK
| | - C. Sha
- Bioinformatics group, IMCB; University of Leeds; Leeds UK
| | - A. Clipson
- Division of Molecular Histopathology; University of Cambridge; Cambridge UK
| | - M. Wang
- Division of Molecular Histopathology; University of Cambridge; Cambridge UK
| | - R.M. Tooze
- Faculty of Medicine and Health; University of Leeds; Leeds UK
| | - M.A. Care
- Faculty of Medicine and Health; University of Leeds; Leeds UK
| | - G.O. Griffiths
- Southampton Clinical Trials Unit; University of Southampton; Southampton UK
| | - M. Du
- Division of Molecular Histopathology; University of Cambridge; Cambridge UK
| | - D.R. Westhead
- School of Molecular and Cellular Biology; University of Leeds; Leeds UK
| | - C. Burton
- Haematological Malignancy Diagnostic Service, Haematological Malignancy Diagnostic Service; St. James's Institute of Oncology, Leeds; Leeds UK
| | - A. Jack
- Haematological Malignancy Diagnostic Service, Haematological Malignancy Diagnostic Service; St. James's Institute of Oncology, Leeds; Leeds UK
| | - P.W. Johnson
- Cancer Research UK Centre; University of Southampton (PMAL Consortium); Southampton UK
| |
Collapse
|
48
|
Eyre T, Phillips E, Linton K, Kassam S, Gibb A, Allibone S, Peggs K, Burton C, Stewart G, Ledieu R, Booth C, Osborne W, Miall F, Eyre D, Ardeshna K, Collins G. RESULTS OF a MULTICENTRE UK-WIDE STUDY EVALUATING THE EFFICACY OF BRENTUXIMAB VEDOTIN IN RELAPSED, REFRACTORY CLASSICAL HODGKIN LYMPHOMA IN THE PRE-TRANSPLANT NAÏVE SETTING. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_70] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- T.A. Eyre
- Haematology; Oxford University Hospitals NHS Trust; Oxford UK
| | - E.H. Phillips
- Department of Haematology; University College London Hospitals NHS Foundation Trust; London UK
| | - K.M. Linton
- Department of Medical Oncology; The Christie Hospital NHS Trust; UK
| | - S. Kassam
- Department of Haematology; Kings College London Hospitals NHS Foundation Trust; UK
| | - A. Gibb
- Department of Medical Oncology; The Christie Hospital NHS Trust; UK
| | - S. Allibone
- Department of Medical Oncology; The Christie Hospital NHS Trust; UK
| | - K. Peggs
- Department of Haematology; University College London Hospitals NHS Foundation Trust; London UK
| | - C. Burton
- Department of Haematology; Leeds Teaching Hospital NHS Trust; Leeds UK
| | - G. Stewart
- Department of Haematology; Leeds Teaching Hospital NHS Trust; Leeds UK
| | - R. Ledieu
- Department of Haematology; St Bartholomew's Hospital; London UK
| | - C. Booth
- Department of Haematology; St Bartholomew's Hospital; London UK
| | - W. Osborne
- Department of Haematology; Newcastle upon Tyne NHS Foundation Trust; Newcastle UK
| | - F. Miall
- Department of Haematology; University Hospitals of Leicester NHS Trust; Leicester UK
| | - D.W. Eyre
- Nuffield Department of Medicine; University of Oxford; Oxford UK
| | - K. Ardeshna
- Department of Haematology; University College London Hospitals NHS Foundation Trust; London UK
| | - G.P. Collins
- Haematology; Oxford University Hospitals NHS Trust; Oxford UK
| |
Collapse
|
49
|
Goodlad J, van Hoppe S, Ahmed S, Barrans S, Painter D, Care M, Taylor J, Evans P, Bentley M, Tooze R, Smith A, Crouch S, Roman E, Westhead D, Burton C. Molecular analysis of primary cutaneous diffuse large B-cell lymphoma, leg type. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
| | | | - S. Ahmed
- HMDS; Leeds Cancer Centre; Leeds UK
| | | | - D. Painter
- Epidemiology and Cancer Statistics; University of York; York UK
| | - M. Care
- Institute of Molecular and Cellular Biology; University of Leeds; Leeds UK
| | | | - P. Evans
- HMDS; Leeds Cancer Centre; Leeds UK
| | - M. Bentley
- Institute of Molecular and Cellular Biology; University of Leeds; Leeds UK
| | - R.M. Tooze
- Institute of Molecular and Cellular Biology; University of Leeds; Leeds UK
| | - A. Smith
- Epidemiology and Cancer Statistics; University of York; York UK
| | - S. Crouch
- Epidemiology and Cancer Statistics; University of York; York UK
| | - E. Roman
- Epidemiology and Cancer Statistics; University of York; York UK
| | - D.R. Westhead
- Institute of Molecular and Cellular Biology; University of Leeds; Leeds UK
| | | |
Collapse
|
50
|
Bentley M, Barrans S, Ahmed S, Taylor J, Burton C, Care M, Sha C, Westhead D. Pan-lymphoma classification. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_31] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- M.A. Bentley
- Institute of Molecular and Cellular Biology; University of Leeds; Leeds UK
| | - S. Barrans
- PNH National Service; Haematology Malignancy Diagnostic Service; Leeds UK
| | - S.M. Ahmed
- PNH National Service; Haematology Malignancy Diagnostic Service; Leeds UK
| | - J. Taylor
- PNH National Service; Haematology Malignancy Diagnostic Service; Leeds UK
| | - C. Burton
- PNH National Service; Haematology Malignancy Diagnostic Service; Leeds UK
| | - M.A. Care
- Institute of Molecular and Cellular Biology; University of Leeds; Leeds UK
| | - C. Sha
- Institute of Molecular and Cellular Biology; University of Leeds; Leeds UK
| | - D. Westhead
- Institute of Molecular and Cellular Biology; University of Leeds; Leeds UK
| |
Collapse
|